Recommendations and Guidelines for Preoperative Evaluation of the Surgical Patient with Emphasis on the Cardiac Patient for Non-cardiac Surgery
Recommendations and Guidelines
For Preoperative Evaluation
Of the Surgical Patient
With Emphasis on the Cardiac Patient
For Non-cardiac Surgery

John H. Tinker, M.D.
Professor and Chair
Anesthesiology Department
University of Nebraska Medical Center

Richard R. Miles, M.D.  Myrna C. Newland, M.D.
Associate Professor and Associate Professor
Chief, Section of Cardiology Anesthesiology

Barbara J. Hurlbert, M.D.
Professor, Anesthesiology
Medical Director, Anesthesia Preoperative Evaluation Unit

Barbara J. Sink, MPAS, PA-C
Anesthesia Preoperative Evaluation Unit

Kathi M. Healey, R.N., M.S.N.
Nurse Practitioner
Clinical Director, Lipid Clinic

Stephen J. Froscheiser, B.S.
Computing Support

Bill Wassom, B.A.
Graphic Designer

University of Nebraska Medical Center
2006
Preoperative preparation of the patient for non-cardiac surgery may be complex. The variety of presenting conditions may be difficult to define prior to surgery:

- What tests should be ordered?
- When is a long-standing condition in satisfactory control, or should some additional study or medication be added prior to operation?
- What are the risks of anesthesia and of the operation for the patient?

The following collection of information from many sources is designed to be a quick reference for anyone who is involved in the preparation of the patient for non-cardiac surgery. These are proposed guidelines and in no way should supersede good clinical evaluation and assessment.

The following information has been reviewed by Richard R. Miles, M.D., Cardiology; Myrna C. Newland, M.D., Anesthesiology; B. Timothy Baxter, M.D., Vascular Surgery; and Frank O. Hayworth, M.D., Anesthesiology. Compilation of the following references was through the efforts of Barbara J. Sink, PA-C, Anesthesia Preoperative Evaluation Unit; Kathi M. Healey, R.N., M.S.N., Cardiology; and computing support from Stephen J. Froscheiser, B.S., Anesthesia Preoperative Evaluation Unit.

Myrna C. Newland, M.D.
Associate Professor
Anesthesiology
University of Nebraska Medical Center
Table of Contents

Classification
- Conditions for Preoperative Evaluation ............................ 4
- Preoperative Algorithm .............................................. 6
- Surgical Classification ............................................. 7
- ASA Classification .................................................. 11

Cardiovascular
- Cardiovascular Evaluation Guidelines ............................... 12
- Vascular Surgery Addendum ........................................... 17
- Preoperative Physical Exam .......................................... 18
- Cardiac Murmurs ..................................................... 20
- Reading an EKG ....................................................... 25
- NYHA Classification of CHF
  - Pathology-Unstable Angina ....................................... 32
- Syndromes with Associated Cardiovascular Involvement .... 35
- Down’s Syndrome .................................................... 38
- Antihypertensive Therapy ............................................ 39
- Pheochromocytoma .................................................... 40
- Ischemic Heart Disease ................................................ 42
- Echocardiography ..................................................... 46
- Prophylaxis Guidelines for Endocarditis ......................... 48

Anesthesia
- Cardiac Risk Stratification ........................................... 54
- Difficult Airway Algorithm .......................................... 57
  (Note also: Down’s Syndrome, 30)
- States That Influence Airway Management .................... 58
- NPO Status for Surgical Patients ................................. 61
- Pulmonary Function Tests .......................................... 62
- The Assessment of Dyspnea ........................................ 64

Labs
- Preoperative Test Recommendation Guidelines ................ 65
- Patient Charges: Inpatient/Outpatient ............................ 66
- Information for Blood Typing ...................................... 69
- Normal Lab Ranges ................................................... 70

Medications/Chemotherapy
- Medications to Be Avoided Prior to Surgery .................. 72
- Drug Allergy vs. Drug Intolerance ............................... 74
- Chemotherapy/Toxicity ............................................. 76

Blood Product Risks .................................................. 79

General Information
- Telephone Number List ............................................. 80
- Reference Chart ..................................................... 81
Conditions for Which Preoperative Evaluation Is Strongly Recommended Prior to the Day of Surgery

General
- Medical condition inhibiting ability to engage in normal daily activity
- Medical conditions necessitating continual assistance or monitoring at home within the past 6 months
- Admission within the past 2 months for acute or exacerbation of chronic condition

Cardiocirculatory
- History of angina, coronary artery disease, myocardial infarction
- Symptomatic arrhythmias
- Poorly controlled hypertension (diastolic >110, systolic >160)
- History of congestive heart failure

Respiratory
- Asthma/COPD requiring chronic medication or with acute exacerbation and progression within past 6 months
- History of major and/or lower airway tumor or obstruction
- Upper and/or lower airway tumor or obstruction
- History of chronic respiratory distress requiring home ventilator assistance or monitoring

Endocrine
- Non-diet controlled diabetes (insulin or oral hypoglycemic agents)
- Adrenal disorders
- Active thyroid disease

Neuromuscular
- History of seizure disorder or other significant CNS disease (e.g., multiple sclerosis)
- History of myopathy or other muscle disorders

Hepatic
- Any active hepatobiliary disease or compromise
Musculoskeletal
• Kyphosis and/or scoliosis causing functional compromise
• Temporomandibular joint disorder
• Cervical or thoracic spine injury

Oncology
• Patients receiving chemotherapy
• Other oncology process with significant physiologic residual or compromise

Gastrointestinal
• Massive obesity (>140% ideal body weight)
• Hiatal hernia
• Symptomatic gastroesophageal reflex

Clinical Anesthesia Updates. Preanesthesia Evaluation of the Surgical Patient, vol. 6, #2, p. 5. L. Reuven Pasternak, M.D., M.P.H.
Preoperative Evaluation
by Primary Team
Determine: ASA status (table 9-3)
surgery classification

ASA 1
order appropriate
labs, CXR, EKG
(per table 23.11)

Normal findings
PTC visit
schedule pt. in O.R.

abnormal findings

Correctable labs
(or normal)
Corrected w/no
further abnormalities
*PTC visit

*PTC visit
Schedule in O.R.

Normal w/no
other abnormalities

CXR

EKG

LABS

abnormal findings other than correctable
labs (refer to ASA #2)

*PTC visit
Schedule in O.R.

Normal findings
PTC visit
schedule in O.R.

abnormal findings

CT or Pulmonary
consult as indicated

appropriate
follow up completed

*PTC visit
schedule in O.R.

PTC visit
refer to algorithm
(10-2)

if no consult
required

*PTC visit
schedule pt. in O.R.

LABS

Correctable labs
(or normal)
Corrected w/no
further abnormalities
*PTC visit

*PTC visit
schedule in O.R.

Normal w/no
other abnormalities

CT or Pulmonary
consult as indicated

appropriate
follow up completed

*PTC visit
schedule in O.R.

Normal findings
PTC visit
schedule in O.R.

abnormal or
abnormal findings
on cardiac exam

cardiology
consult required

pt. cleared
for surgery
*PTC visit
scheduled pt.
in O.R.

further follow
up by cardiology
required prior
to scheduling pt.
for surgery

If no consult
required

*PTC visit
schedule pt.
in O.R.

* PT SHOULD BRING H&P, CHART,
SURGICAL CONSENT, BLOOD CONSENT
AND ORDERS WITH THEM TO THE P.T.C.

U.S.C. weight limit
300 lbs
Page 7777
if over 300#

PFT’s: intrathoracic or extrathoracic mass
lobectomy w/ possible pneumoetomy.

Bedside PFT’s: thoracic procedure or major abdominal
procedure with preexisting pulmonary
disease (moderate-severe).

ABG’s: suspected CO2 retainer
(if abnormal, obtain PFT’s)
(Guide to Estimation of Physiological Trespass)

Category 1

Minimal risk to the patient independent of anesthesia

Minimally invasive procedures with little or no blood loss

Often done in office setting with the operating room used principally for anesthesia & monitoring

Includes:

- Breast biopsy
- Removal of minor skin or subcutaneous lesions
- Myringotomy tubes
- Hysteroscopy
- Cystoscopy
- Vasectomy
- Circumcision
- Fiberoptic bronchoscopy

Excludes:

- Open exposure of internal body organs
- Repair of vascular or neurologic structures
- Placement of prosthetic devices
- Entry into abdomen, thorax, neck, cranium, or extremities
- Postoperative monitored care setting (ICU, ACU)
- Open exposure of abdomen, thorax, neck, cranium
- Resection of major body organs
Category 2

Minimal to moderately invasive procedure

Blood loss less than 500 cc

Mild risk to patient independent of anesthesia

Includes:

- Diagnostic laparoscopy
- Dilation & curettage
- Fallopian tubal ligation
- Arthroscopy
- Inguinal hernia repair
- Laparoscopic lysis of adhesions
- Tonsillectomy/adenoidectomy
- Umbilical hernia repair
- Septoplasty/rhinoplasty
- Percutaneous lung biopsy
- Laparoscopic cholecystectomy

Extensive superficial procedures

Excludes:

- Open exposure of internal body organs
- Repair of vascular or neurologic structures
- Placement of prosthetic devices
- Postoperative monitored care
- Major vascular repair (e.g., aortofemoral bypass)
- Planned postoperative monitored care setting (ICU, ACU)
Category 3

Moderately to significantly invasive procedure

Blood loss potential 500–1,500 cc

Moderate risk to patient independent of anesthesia

Includes:

Thyroidectomy
Hysterectomy
Myomectomy
Cystectomy
Cholecystectomy
Laminectomy
Hip/knee replacement
Nephrectomy
Major laparoscopic procedures
Resection, reconstructive surgery of the digestive tract

Excludes:

Open thoracic or intracranial procedure
Major procedure on the oropharynx
Major vascular, skeletal, neurologic repair
Category 4

Highly invasive procedure

Blood loss greater than 1,500 cc

Major risk to patient independent of anesthesia

Includes:

Major orthopedic-spinal reconstruction

Major reconstruction of the gastrointestinal tract

Major genitourinary surgery (e.g., radical retropubic prostatectomy)

Major vascular repair without postoperative ICU stay

Category 5

Highly invasive procedure

Blood loss greater than 1,500 cc

Critical risk to patient independent of anesthesia

Usual postoperative ICU stay with invasive monitoring

Includes

Cardiothoracic procedure

Intracranial procedure
**Physical Classification of the American Society of Anesthesiologists (ASA)**

<table>
<thead>
<tr>
<th>Status</th>
<th>Disease State</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA Class 1</td>
<td>No organic, physiologic, biochemical, or psychiatric disturbance.</td>
</tr>
<tr>
<td>ASA Class 2</td>
<td>Mild to moderate systemic disturbance that may or may not be related to the reason for surgery. Examples: Heart disease that only slightly limits physical activity, essential hypertension, diabetes mellitus, anemia, extremes of age, morbid obesity, chronic bronchitis</td>
</tr>
<tr>
<td>ASA Class 3</td>
<td>Severe systemic disturbance that may or may not be related to the reason for surgery, <em>(does limit activity)</em>. Examples: Heart disease that limits activity, poorly controlled essential hypertension, diabetes mellitus with vascular complications, chronic pulmonary disease that limits activity, angina pectoris, history of prior myocardial infarction</td>
</tr>
<tr>
<td>ASA Class 4</td>
<td>Severe systemic disturbance that is life-threatening with or without surgery. Examples: Congestive heart failure, persistent angina pectoris, advanced pulmonary, renal, or hepatic dysfunction</td>
</tr>
<tr>
<td>ASA Class 5</td>
<td>Moribund patient who has little chance of survival but is submitted to surgery as a last resort <em>(resuscitative effort)</em>. Examples: Uncontrolled hemorrhage as from a ruptured abdominal aneurysm, cerebral trauma, pulmonary embolus.</td>
</tr>
</tbody>
</table>

**Emergency Operation (E)**

Any patient in whom an emergency operation is required

Example: An otherwise healthy 30-year-old woman who requires a dilation and curettage for moderate but persistent hemorrhage (ASA Class 1 E)

From information in American Society of Anesthesiologists
**STEP 1**
Need for noncardiac surgery
- Urgent or elective surgery
- Coronary revascularization within 5 yr?
- Recent coronary evaluation

**STEP 2**
- Recurrent symptoms or signs?
  - Yes
  - No
- Recent coronary angiogram or stress test?
  - Yes
  - No
- Unfavorable result or change in symptoms

**STEP 3**
- Clinical predictors
  - Major clinical predictors**
  - Intermediate clinical predictors
  - Minor or no clinical predictors

**STEP 4**
- Consider delay or cancel noncardiac surgery
- Consider coronary angiography

**STEP 5**
- Medical management and risk factor modification
- Subsequent care dictated by findings and treatment results

**STEP 6**
- Operating Room

**STEP 7**
- Operating Room

---

Major Clinical Predictors**
- Unstable coronary syndrome
- Decompensated CHF
- Significant arrhythmias
- Severe valvular disease

* Pheochromocytoma
* Down's Syndrome
(see attachments)
**STEP 6**

Clinical predictors

**STEP 8**

Functional capacity

Surgical risk

Noninvasive testing

Invasive testing

**Intermediate clinical predictors†**

- Poor (<4 METs)
  - High surgical risk procedure
  - Noninvasive testing
  - Consider coronary angiography
  - Subsequent care* dictated by findings and treatment results

- Moderate or excellent (>4 METs)
  - Intermediate surgical risk procedure
  - Operating room
  - Consider coronary angiography
  - Subsequent care* dictated by findings and treatment results

- Low surgical risk procedure
  - Postoperative risk stratification and risk factor reduction

**Noninvasive testing**

- Low risk
  - Operating room
  - Consider coronary angiography
  - Subsequent care* dictated by findings and treatment results

**Invasive testing**

- High risk
  - Consider coronary angiography
  - Subsequent care* dictated by findings and treatment results

**Intermediate Clinical Predictors†**

- Mild angina pectoris
- Prior MI
- Compensated or prior CHF
- Diabetes mellitus
- Renal insufficiency
Stepwise approach to preoperative cardiac assessment. Steps are discussed in text. *Subsequent care may include cancellation or delay of surgery, coronary revascularization followed by noncardiac surgery, or intensified care.
Cardiovascular Evaluation for Noncardiac Surgery

Name: ________________________________  Vitals: __________

Cardiac Meds:

Surgery Risk:
High ________  Intermediate ________  Low ________
(Emergency surgery; (Carotid endarterectomy; head & neck; (Endoscopic; superficial procedure;
Aortic & major vascular; PV surgery; procedures & blood loss or intraperitoneal; intrathoracic; orthopaedic; prostate)
large fluid shifts)

Existing Cond:
CHF: _______________  Angina Stable/Unstable
(Compensated/decompensated)
MI _______________  Arrhythmias _______________ >5 PVC/min
CABG ≥5 yrs ________  ≤5 yrs ________  AICD ________
Valvular Disease w/o repair/replacement _____  Pacer ________
AAA w/o repair _______  IHSS ________
Cardiac Arrest ________  BBB/Sick Sinus __________

Risk Factors:
Age _______________  Family Hx. _______________
Sex __________________  HTN _______________
Obesity _______________  Hypercholesteremia _______________
Smoking _______________  Comorbid Conditions: ____________
DM  COPD
PVD  TIA/CVA

Poor General Med. Condition
1. Electrolyte abn. (K⁺ ≤3.0 meq/l or HCO₃⁻ ≤ meq/l)
2. Renal insufficiency (BUN ≥50 mg/dl or creat. ≥3.0 mg/dl)
3. Abnormal ABG’s (PO₂ ≤ 60 mmHg or PCO₂ ≥ 50 mm Hg)
4. Abnormal liver status
5. Chronically bedridden
Meds: (possible cardiac toxicity)
Symptoms/findings:
- dyspnea
- palpitations
- rales
- orthopnea
- syncopal episodes
- peripheral edema
- chest pain
- lightheadedness
- cardiomegaly
- pulmonary edema/
- tortuous or calcified
- infiltrates
- abnormal EKG
- aorta on CXR
- in past—yes____

Duke Activity Status Index:
1–4 METS(Eating, dressing, walking around house, dishwashing)
4–10 METS(Climbing stairs—1 flight, walking level ground 6.4 km/hr, run-
ning short distance, game of golf)
≥10 METS(Swimming, singles tennis, football)
MET: metabolic equivalent. 1 MET = 3.5 mL of O₂/Kg/min.

Results:
- EKG___________
- ECHO __________
- CATH __________
- STRESS________
- CXR____________

1. Have you had any chest pain? yes/no
2. Have you experienced breathlessness on exertion? yes/no
3. Have you experienced breathlessness lying flat? yes/no
4. Has any form of heart disease ever been diagnosed? yes/no
5. Have you had rheumatic fever? yes/no
6. Have you ever been found to have a heart murmur? yes/no

Response to: Recommendations and Guidelines for Preoperative Evaluations

This is a very inclusive document which covers the basics of anesthesia preoperative evaluation. The crux of this handout is the algorithm which outlines the preoperative cardiac assessment. Although I generally agree with this outline, there were a few places which may result in unnecessary preoperative noninvasive testing:

1. Under Step 6 in patients with moderate or excellent functional capacity undergoing high-risk surgical procedures. I am assuming that the high-risk procedures may include lower extremity bypass, aortic aneurysm repair, and carotid endarterectomy. Noninvasive testing will invariably be positive in many of these patients. There is, to my knowledge, no good data to support a role for coronary revascularization in a patient with moderate or excellent functional capacity. I would suggest at this decision point that a second option would be to undergo an operation with invasive preoperative monitoring and optimization.

2. Under Step 7 in the high surgical risk procedure group with minor clinical predictors, I would also suggest that a decision be made prior to noninvasive testing to consider a surgical procedure with invasive preoperative monitoring. These decisions should be made between the surgeon and the patient with the understanding of what the risk entails.

An article published in the Journal of the American Medical Association, which used computer modeling to assist the outcome of vascular surgery in patients who were moderately or mildly symptomatic, demonstrated an increased mortality in patients who underwent a preoperative evaluation. This was related to the fact that coronary revascularization, because of its own inherent risks, does not lower the overall operative mortality. Therefore, I would submit that we may be doing patients a disservice in these categories by not giving them the option of going directly to surgery. I think the data from the Portland group published in the Journal of Vascular Surgery, in which none of these patients with intermediate or minor clinical predictors were evaluated, and the overall operative mortality was <2%, clearly shows that it is unnecessary to subject these patients to noninvasive testing and possible coronary angiography. Especially considering the cost of this and the probability that the overall recommendation would simply be to use invasive monitoring.

Sincerely,

B. Timothy Baxter, M.D.
Associate Professor
Department of Surgery
Preoperative Physical Examination

**Vital Signs:**
Current values and range while hospitalized

**Height, Weight:**
For calculation of drug dosages and pump flows

**Airway:**
Anatomic features that could make mask ventilation or intubation difficult

**Neck:**
Jugular venous distention (CHF)
Carotid bruit (cerebrovascular disease)
Landmarks for jugular vein cannulation

**Heart:**
Murmurs characteristic of valve lesions
$S_3$ (increased LVEDP)
$S_4$ (decreased compliance)
Click (MVP) or rub (pericarditis)
Lateral PMI displacement (cardiomegaly)
Precordial heave, lift (hypertrophy, wall motion abnormality)

**Lungs:**
Rales (CHF)
Rhonchi, wheezes (COPD)

**Vasculature:**
Sites for venous and arterial access
Peripheral pulses

**Abdomen:**
Pulsatile liver (CHF, tricuspid regurgitation)

**Extremities:**
Peripheral edema (CHF)

**Nervous System:**
Motor or sensory deficits

Preoperative Findings Suggestive of Ventricular Dysfunction

**History:**
History of MI, intermittent or chronic CHF
Symptoms of CHF: fatigue, DOE, orthopnea, PND, ankle swelling

**Physical Examination:**
Hypotension/tachycardia (severe CHF)
Prominent neck veins, laterally displaced apical impulse, $S_3$, $S_4$, rales, pitting edema, pulsatile liver, ascites (tricuspid regurgitation)

**Electrocardiogram:**
Ischemia/infarction, rhythm, or conduction abnormalities

**Chest X-ray:**
Cardiomegaly, pulmonary vascular congestion/pulmonary edema, pleural effusion, Kerley B lines

**Cardiac Testing:**
Cath data—LVEDP >18, EF <0.4, Cl <2.0 l/min⁻¹/min⁻²
Echocardiography—low EF, multiple regional wall motion abnormalities
Ventriculography—low EF, multiple areas of hypokinesis, akinesis, or dyskinesis


Grading of Cardiac Murmurs

I. Faintest audible; can be heard only with special effort
II. Faint, but easily audible
III. Moderately loud
IV. Loud; associated with a thrill
V. Very loud; associated with a thrill. May be heard with a stethoscope off chest
VI. Maximum loudness; associated with a thrill; heard without a stethoscope

Practical Guide to the Care of the Medical Patient, 2nd ed. Fred F. Ferri, M.D. Chapter 3, p. 18
# CARDIAC MURMURS

<table>
<thead>
<tr>
<th>MURMUR</th>
<th>LOCATION</th>
<th>CHARACTER</th>
<th>DIFFERENTIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Still’s –benign pediatric Murmur</strong></td>
<td>LLSB to apex</td>
<td>Coarse, vibrating early systolic; S₂ splits and closes normally, murmur diminishes with sitting or deep inspiration</td>
<td>VSD, MVP, IHHS</td>
</tr>
<tr>
<td><strong>Venous hum –benign pediatric murmur</strong></td>
<td>Neck, USB apex just above the clavicle either medial to the sternocleidomastoid or between its insertions, more on right side</td>
<td>Continuous, gone when supine</td>
<td>PDA, AVMs</td>
</tr>
<tr>
<td><strong>MVP (Mitral Valve Prolapse) (Barlow’s syndrome), associated with various inherited connective tissue diseases including Ehlers-Danlos, Marfan’a, Osteogenesis imperfecta, von Willebrand’s</strong></td>
<td>Heard best at apex</td>
<td>Midsystolic click (92%). Crescendo mid-to-late systolic murmur (85%) that moves toward S₃ with standing or other decrease in venous return</td>
<td>Sx: Palpitations (PACs, PVC’s, premature junctional)</td>
</tr>
<tr>
<td><strong>Aortic Stenosis- most common in elderly now. Rarely (10%) due to RHD, most is calcific aortic stenosis on bicuspid or previously normal valve</strong></td>
<td>Loud ejection murmur maximum at base and transmitted into neck vessels, often associated with a thrill or ejection click; no MR unlike in IHSS; ejection click (split first heart sound) radiates into carotids The ejection murmur may be soft, distant in patients with low cardiac output, obesity and/or COPD Strong apical impulse Narrowing of pulse pressure —later stage may have a necrotic notch on carotid upstroke Significant if area &lt;0.8cm²/M² or mean gradient ≥ 35mmHg</td>
<td>Loud rough systolic diamond shaped murmur Sx: Often ax, fatigue, exertional dyspnea, Angina, CHF, syncope, dysphagia SI: BP normal; narrow pulse pressure; Cmplc: Angina, sudden death, GI-angiodysplasia with GI bleed, ischemia, Vtach/fib CHF, SBE, heart blocks EKG: normal, or LVH and strain, ST-T wave changes CXR: May show 4—chamber enlargement, valvular calcifications usually only with significant disease, LVH, poststenotic dilation of ascending aorta, pulmonary congestion</td>
<td>R/O bicuspid aortic valve Accentuation: Valsalva release Sudden squatting Passive leg raising Decrease: Handgrip Valsalva Standing</td>
</tr>
<tr>
<td><strong>Aortic Insufficiency, severe rarely due to RHD, usually due to trauma, syphilis, dissecting aneurysm, endocarditis, SLE, RA, ankylosing spondylitis</strong></td>
<td>S, heard over the apex, LSB at 3rd or 4th intercostal space Displacement of cardiac impulse downward and to the patient’s left the aortic regurgitant murmur is difficult to hear if the heart rate is greater than 90 bpm</td>
<td>Decrescendo, blowing diastolic murmur, early systolic apical ejection murmur Sx: Austin Flint murmur (low pitched apical diastolic rumble heard in severe AR), syncope, chest pain, dyspnea on exertion SI: widened pulse pressure, bounding pulses, head “bobbing” with each systole, “water hammer; or collapsing pulse “Corrigan’s pulse) at the wrist, capillary pulsations (Quincke’s pulse) base of nail beds, ”double Duroziez” a “to and fro” murmur over femoral arteries EKG: LVH CXR: LVH, aortic dilation</td>
<td>Accentuation: Sudden squatting Isometric handgrip Sitting up and leaning forward</td>
</tr>
</tbody>
</table>
## CARDIAC MURMURS

<table>
<thead>
<tr>
<th>MURMUR</th>
<th>LOCATION</th>
<th>CHARACTER</th>
<th>DIFFERENTIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mitral Stenosis</strong></td>
<td>Significant if valve diameter &lt;1.2cm²</td>
<td>mid-diastolic murmur with presystolic accentuation even in Afib; opening</td>
<td>Accentuation: Exercise, Left lateral position, Isometric handgrip, Coughing, After Valsalva, Squatting</td>
</tr>
<tr>
<td></td>
<td>History of and/or high risk for peripheral</td>
<td>snap; loud S₁, rumbling, Right ventricular “lift” over lower sternum</td>
<td></td>
</tr>
<tr>
<td></td>
<td>arterial embolus especially if Afib is</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>present</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mitral Regurgitation</strong></td>
<td>Holosystolic murmur at apex with radiation to</td>
<td><strong>Sx:</strong> Exertional dyspnea, orthopnea, fatigue, Frank CHF, hemoptysis</td>
<td>Accentuation: Sudden squatting, Isometric handgrip, Decrease: Valsalva, Standing</td>
</tr>
<tr>
<td></td>
<td>base or left axilla and Left posterior intra-</td>
<td>(caused by pulmonary hypertension)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>scapular area Hyperdynamic apex often with</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>palpable left ventricular lift and apical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>thrill</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In chronic mitral regurgitation the murmur</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>maybe heard middial to left scapula secondary to severe left atrial enlargement</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tricuspid Stenosis</strong></td>
<td>RV area</td>
<td>Diastolic, scratchy</td>
<td>Accentuation: Inspiration, Passive leg raising, Right lateral decubitus, Decrease: Expiration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increase during moving inspirations</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jugular venous distension with failure to collapse on inspiration</td>
<td></td>
</tr>
<tr>
<td><strong>Tricuspid Insufficiency</strong></td>
<td>Best at LLSB, occasionally best at epigastrium, at the RSB or if the RV is very large, over the mid-left thorax at the site of the usual LBV apex usually accompanied by RVS₃</td>
<td>Pansystolic that increases with inspiration at the LLSB, (or whereever a palpable RV lift is felt-Carvallo sign)</td>
<td>Accentuation: Inspiration, Passive leg raising, By exercise, By pressure over or just below the liver, Decrease: Expiration</td>
</tr>
</tbody>
</table>

|                        |                                |                                |                                |                                |                                |                                |                                |                                |                                |
## Cardiac Murmurs

<table>
<thead>
<tr>
<th>Murmur</th>
<th>Location</th>
<th>Character</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>VSD</td>
<td>LLSB, Apical</td>
<td>Intolerant of decreased blood volume, &amp; venous return, as it increases murmur intensity and outflow tract gradient</td>
<td>R/O: “athlete’s heart” w LV wall thickness always &lt;16mm, rarely &gt;13mm, which overlaps w IHSS in men but not in women</td>
</tr>
<tr>
<td></td>
<td>Frequently left chest will be more prominent than right with larger VSDs</td>
<td>Diaphasic arterial systolic pulse, best palpated in the carotid arteries Aortic murmur without radiation into neck</td>
<td>Accentuation: Valsalva strain opposite of A.S. Standing Exercise Etoh</td>
</tr>
<tr>
<td>Pulmonic Stenosis</td>
<td>ULSB, neck and back</td>
<td>P₂, diminished; loud ejection murmur at upper left sternal border neck and back; ejection click, decreases with inspiration RV lift is gradient is significant</td>
<td>Accetuation: Valsalva release Decrease: Expiration</td>
</tr>
<tr>
<td>Systolic murmur</td>
<td>2nd Left interspace</td>
<td>Sx: fatigue dyspnea, cyanosis, CHF Si: CHF including hepatomegaly in children</td>
<td></td>
</tr>
<tr>
<td>IHSS (Idiopathic hypertrophic subaortic stenosis) Genetic positive family history in 1/3 Abnormal Intraventricular septum produces dynamic aortic root obstruction and subaortic stenosis; mitral regurgitation is due to anterior mitral leaflet being distorted by the septum Administration of inotropic drugs may cause/worsen shock and/or cardiac arrhythmias</td>
<td>Loud systolic LSB murmur after inotropes given SAM (systolic anterior motion of the mitral leaflet)</td>
<td>Diaphasic arterial systolic pulse, best palpated in the carotid arteries Aortic murmur without radiation into neck</td>
<td>R/O: “athlete’s heart” w LV wall thickness always &lt;16mm, rarely &gt;13mm, which overlaps w IHSS in men but not in women</td>
</tr>
<tr>
<td>Graham-Steell murmur-</td>
<td>LSB &gt; RSB</td>
<td>Diastolic decrescendo murmur heard in severe pulmonary hypertension, secondary to pulmonary regurg High pitched, often increases with inspiration</td>
<td>Accentuation: Valsalva strain opposite of A.S. Standing Exercise Etoh</td>
</tr>
<tr>
<td>high pressure in the pulmonary artery</td>
<td></td>
<td>Sx: dyspnea, syncope chest pain, angina that starts when exercise stops, palpitation Cmple:Sudden death by Ventricular fibrillation</td>
<td>Decrease: Handgrip Squatting Leg elevation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cmple: SBE, CHF, pulmonary hypertension, with Eisenmenger’s 2/3 die in pregnancy EKG: normal unless huge left-to-right causing LVH; RVH suggests fixed pulmonary hypertension and left atrial enlargement</td>
</tr>
<tr>
<td>Pulmonary Regurgitation</td>
<td></td>
<td>Slight delay after the P₂ before any murmur is heard, even if it starts with the P₂, the murmur tends to be short and rough, decrescendo</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EKG: normal or LVH + strain; P pulmonale CXR: PA dilatation, RVH, diminished pulmonary vasculature</td>
</tr>
<tr>
<td>Accentuation: Valsalva release Decrease: Expiration</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# CARDIAC MURMURS

<table>
<thead>
<tr>
<th>MURMUR</th>
<th>LOCATION</th>
<th>CHARACTER</th>
<th>DIFFERENTIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coarctation of the aorta</td>
<td>Left upper back or</td>
<td>Systolic murmur</td>
<td>Coarctation of the aorta, AS/AR</td>
</tr>
<tr>
<td>Associated with PDA, bicuspid aortic valve</td>
<td>pulmonic area</td>
<td>Sx: CHF, leg pains, &amp; fatigue, headaches - rarely in childhood; CHF in</td>
<td>R/O : coronary AV fistula, Ruptured sinus of Valsalva, Coarctation of aorta</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3rd-4th decades</td>
<td>AS/AR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Si: hypertension in arms, normal or low BP in legs; decreased/delayed</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>femoral pulses compared to radial pulses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cmplc: SBE, intracranial bleeding, hypertensive encephalopathy; ruptured</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>/dissected aorta; hypertensive cardiovascular disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Risk of aortic dissection remains even after repair</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EKG: normal, or LVH; RVH, suggests a PDA beyond the coarct</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CXR: normal heart, and pulmonary vasculature; coarct visible on plain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>chest occasionally “notch” in aortic root shadow; rib notching in older</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>patients</td>
<td></td>
</tr>
<tr>
<td>PDA (Patent Ductus Arteriosus)</td>
<td>Left base</td>
<td>“Machinery” murmur or Gibson murmur or “to &amp; fro” murmur</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>L-to-R shunt, which in end-stage disease reverses to R-to-L shunt</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Eisenmenger’s syndrome) with clubbing and cyanosis; bounding pulses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>indicate wide pulse pressure; pink fingers, blue toes with</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eisenmenger’s</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cmplc: SBE, CHF; pulmonary hypertension; with Eisenmenger’s, 2/3 die in</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>pregnancy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EKG: normal; occasionally LVH: if has RVH, suggest fixed pulmonary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>hypertension</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CXR: Normal, with small PDA; or w larger one, LVH, enlarged aortic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>knob with dilatation of the proximal relative to the distal aorta, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>a large LA with prominent vasculature</td>
<td></td>
</tr>
<tr>
<td>ASD (Atrial Septal Defects)</td>
<td>Apical</td>
<td>Harsh systolic murmur, pansystolic from MR (33%), TI or VSD (75%)</td>
<td></td>
</tr>
<tr>
<td>Primum: AV canal defects including low ASD,</td>
<td></td>
<td>P increased; Fixed Split S2;</td>
<td></td>
</tr>
<tr>
<td>high VSD, cleft mitral and/or tricuspid</td>
<td></td>
<td>Si: cyanosis mild or absent, CHF, RVH</td>
<td></td>
</tr>
<tr>
<td>valves or a common AV valve</td>
<td></td>
<td>Sx: dyspnea, fatigue, CHF, pulmonary infection</td>
<td></td>
</tr>
<tr>
<td>Increased risk in Down’s Syndrome</td>
<td></td>
<td>Cmplc: CHF, pulmonary hypertension, SVT arrhythmias, SBE rarely,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased incidence of rheumatic fever</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EKG: L axis, PRBBB, R and LVH, counterclockwise rotation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CXR: Small aortic knob; RVH and increase pulmonary flow, if MR, then</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>large left atrium and LV, “gooseneck deformity” of LV outflow tract on</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>angiography; serrated MV leaf</td>
<td></td>
</tr>
</tbody>
</table>
## CARDIAC MURMURS

<table>
<thead>
<tr>
<th>MURMUR</th>
<th>LOCATION</th>
<th>CHARACTER</th>
<th>DIFFERENTIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASD:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Secundum:</strong> Mid or upper ASD allows left to right shunt</td>
<td>Upper left sternal border</td>
<td>Mild systolic murmur</td>
<td>Increased risk of atrial arrhythmias</td>
</tr>
<tr>
<td></td>
<td>Lower left sternal border</td>
<td>mid-diastolic rumble form high flow</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>S₂; wide and fixed; RVH</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sx: rarely in infancy or childhood; later dyspnea w CHF and pulmonary HT, palpitations if arrhythmias</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cmplc: CHF and Pulmonary HT late</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EKG:</strong> axis normal or RAD, partial and full RBBB, RVH and strain; clockwise rotation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CXR:</strong> small aortic knob, RVH+ increased pulmonary flow; no LA enlargement unlike patent ductus or VSD</td>
<td></td>
</tr>
</tbody>
</table>

Reviewed and edited by:
Daniel Mathers, M.D., FACC
Cardiology,
UNMC

References
READING AN EKG

RATE:  300 / (# Large squares from R to R)

RHYTHM:
   Is every QRS preceded by P-wave?
   Is the rhythm regular?

MEAN QRS VECTOR:
   Normal: -30 to +90 (degrees)
   LAD:  < - 30
   RAD:  > +90

P-WAVE VECTOR:  +30 to +60
T-WAVE VECTOR:  Within 45 of QRS

INTERVALS (normals):  sec (ms)
   (Note:  1 small square = 0.04 sec)
   PR interval:  0.12-0.20 (120-200)
   QRS duration:  < 0.12 (<120)
   QT interval:  Varies with HR
   RATE    INTERVAL
   125     <0.25 Sec
   75      <0.35 Sec
   45      <0.45 Sec

QRS NOMENCLATURE
   Q-wave = first negative deflection before positive
   R-wave = any positive deflection
   S-wave = first negative after positive

NORMAL EKG:
   P-waves upright in I, II, V2-V6
   T-waves upright in I, II, V3-V6
   inverted in aVR
   variable in III, aVL, aVF, V1, V2
   Small Q-wave normal in I, aVL
   Deep Q-wave (QS) normal in aVR , and
   occasionally seen in III, V1, V2

BASIC EKG ABNORMALITIES

PR INTERVAL:
   <0.12 seconds:
      -normal in tachycardia
      -junctional (nodal) rhythm
      -"pre-excitation":
         Wolff- Parkinson-White syndrome
         ("delta-waves" prolong the QRS)
   >0.20 seconds (1st degree AV block):
      -focal fibrosis
      -digitalis
      -ischemic heart disease
      -rheumatic heart disease
      -hyperkalemia
QRS DURATION: >0.12 SECONDS
- Bundle branch blocks (QRS > or = 0.12)
- Intraventricular conduction delay (IVCD)
- LVH
- Hyperkalemia
- Procainamide, quinidine
- Wolf-Parkinson-White syndrome

QT INTERVAL:
Long QT:
- Cardiac depressants (i.e., quinidine)
- Tricyclic antidepressants
- Ischemic heart disease
- Hypokalemia, hypocalcemia, alkalosis
- Bundle branch block
- Stroke, coma
- Ventricular hypertrophy

Shortened QT:
- Hypercalcemia
- Digitalis

P-WAVE ABNORMALITIES:
Tall peaked P-waves (amplitude > or = 3 mV)
- Usually largest in lead II
- Suggests Right Atrial Abnormality (RAA) (enlargement)
- Often seen in COPD

Broad, notched P-waves > or = 0.12 sec
- Suggests Left Atrial Abnormality (LAA) (enlargement)
- Often seen in Mitral Valve Disease

Biphasic P-wave in lead VI
- May be normal
- Initial deflection > terminal deflection
  - Suggests RAA
- Terminal deflection > initial deflection
  - Suggest LAA

QRS COMPLEX:
Low Amplitude
- Obesity
- COPD
- Effusions -- pleural or pericardial
- Old age -- especially after MI’s
- Hypothyroidism
- Pneumothorax
- Primary cardiomyopathy

Tall QRS
- Ventricular hypertrophy
- Bundle branch block
- Normal for age <35
**Poor R-wave progression**
- lead placement
- clockwise rotation (normal variant)
- anteroseptal MI
- LVH, RVH
- LBBB, LAFB, IVCD
- COPD

Q-waves (see MYOCARDIAL INFARCTION)
- must be > 0.04 sec and/or at least 1/3 the amplitude of the R-wave to be significant

**ST SEGMENT:**

Elevated ST segment
- acute MI (usually focal)
- pericarditis (diffuse)
- ventricular aneurysm (persistent)
- atypical angina (Prinzmetal)
- may be normal variant (early repolarization)

Depressed ST segment
- ischemia/angina pectoris
- digitalis ("scooped out" ST's)
- ventricular hypertrophy-if down sloping called "strain"
- bundle branch block
- hypokalemia/hypomagnesemia

**T-WAVE CHANGES:**

Tall peaked T-waves (5 small boxes in limb leads or 10 small boxes in chest leads)
- hyperkalemia
- hyperacute MI
- normal variant in young

Inverted T-waves
- anything causing ST-depression
- digitalis
- pericarditis-begins upright and flips
- normal variant-persistent juvenile
  - pattern in 10% blacks and children

U-Waves
- from repolarization of papillary muscle
- seen most in precordial leads
- hypokalemia/hypomagnesemia
- most often normal variant

**LEFT AXIS DEVIATION:** (-30 or >)
- LVH
- Left anterior fascicular block
- LBBB
- Inferior MI

**RIGHT AXIS DEVIATION:** (+90 or >)
- MI (lateral)
- RVH
- RBBB
- Left posterior fascicular block (rare)
- COPD
- Acute PE
COMMON CRITERIA FOR EKG DIAGNOSES

RIGHT ATRIAL HYPERTROPHY
- "Peaked" P-waves > 2.5 mV in II, III, or aVF
- Biphasic P-wave in lead VI with positive > negative

LEFT ATRIAL HYPERTROPHY
- Long P-wave > 0.12 sec in any lead (primarily in lead II)
- Biphasic P-wave in lead VI with negative > positive
- Double peaked P-wave in I, II, aVL, V4-V6

LEFT VENTRICULAR HYPERTROPHY (criteria not valid if patient is younger than 35 years old)
- Axis > -15 degrees (nonspecific)
- S in VI or V2 + R in V5 or V6 > 35 mV
- R in V5 or V6 > 26 mV
- R in aVL > 12 mm
- "Strain": ST depression, often with flipped T's in I, II, aVL, V5, V6

LEFT VENTRICULAR HYPERTROPHY
- R > S in V1 and S > R in V6
- Axis > +110 degrees
- "Strain": ST depression, often with flipped T's in V1-V4

RIGHT BUNDLE BRANCH BLOCK (RBBB)
- Prolonged QRS > or = 0.12 sec
- Axis normal or rightward
  (if left axis deviation present, then must have both RBBB and left anterior fascicular block)
- rSR’ pattern in V1, V2 “mutant rabbit ears”
- Terminal (last 0.04 sec) S-wave in V5, V6
- ST depression and T-wave inversion in V1, V2

LEFT BUNDLE BRANCH BLOCK (LBBB)
- Prolonged QRS > or = 0.12 sec
- Axis normal or leftward
- Poor R-wave progression. May have rS or large Q wave in V1, V2, V3, and V4
- Terminal QRS forces (last 0.04 sec) positive in V5 and V6 (pure positive QRS complex in V6)
- T-wave inversion, ST depression & elevation in most leads. (Often exaggerated)

LEFT ANTERIOR FASCICULAR BLOCK (Hemiblock)
- Axis more negative than -45 degrees
- No other cause of axis deviation present
- Normal QRS duration (.10-.11)
- Small Q in I, small R in III (Q1R3 pattern)

LEFT POSTERIOR FASCICULAR BLOCK (Hemiblock)
- Axis more positive than +110 degrees
- No other cause of axis deviation present
- Normal QRS duration
- Small Q in III, small R in I (Q3R1 pattern)
MYOCARDIAL INFARCTION

Progression of changes

- hyperacute (min-hrs): ST evaluation and high “peaked” T-waves
- acute MI (hrs): ST drops but still elevated, T-wave inversion
- Q-waves develop in hours to days
- recent MI (weeks-months): ST returns baseline, T-waves inverted for months to years, and Q-waves remain
- old MI (months-years): Q-waves

Significant Q waves: (must meet one of two criteria)

1) Q wave must be 1/4 (1/3) the size of the R wave to be considered significant
or
2) Q wave is .04 seconds wide (one small box) or greater to be considered significant

Definitions of Transmural (Q-wave) Infarctions

- septal \( V_1 - V_2 \)
- anterior \( V_2 - V_3, V_4 \)
- anteroseptal \( V_1 - V_3, V_4 \)
- high lateral \( I, aVL \)
- anterolateral \( V_5 - V_6, I, aVL \)
- extensive anterior \( V_1 - V_5, V_6 \)
- inferior \( II, III, aVF \)
- inferolateral \( II, III, aVF, V_5 - V_6 \)
- posterior R-wave \( V_1 - V_2 \) with ST depression
- right ventricular \( rV_3 - rV_4 \) with ST depression

NOTE:
- EKG changes in only 80% with MI
- Inferior MI’s commonly result in a BBB
- Q-waves disappear in 20% of patients who had MI

PERICARDITIS

- Diffuse ST elevation (except aVR)
- No reciprocal ST depression
- As pericarditis subsides, ST returns to baseline and T-waves invert

WOLFF-PARKINSON-WHITE SYNDROME (WPW)

- Is considered the Great Mimic. Tends to mimic many other ECG conditions. Is fairly uncommon (2 per 1000) but occurs frequently enough to cause problems for the unwary.
- Short PR interval
- QRS widening
- Presence of delta waves
- Patients with WPW are highly susceptible to certain cardiac arrhythmias. If suspect WPW, do not use digoxin, verapamil or diltiazem.
DIGITALIS
- Digitalis effect: (the degree of changes has no consistent relation to the amount of digitalis admin.)
  -“scooped” out ST depression
  -biphasic T-wave (may show decreased amplitude)
  -shortening of QT
  -prolonged PR

Digitalis toxicity:
- all the above, plus
  -excitatory effects: Digitalis toxicity is known to be capable of producing almost all types of cardiac arrhythmias, except atrial flutter and BBB.
    (i.e., PVC’s, PAT with block), V-Tach, V-Fib, etc.)
  -suppressant effects:
    -sinus bradycardia, SA block, AV blocks

QUINIDINE (similar effects with other-antiarrhythmics)
Therapeutic effects
- Prolonged QT interval
- ST depression
- T-waves depressed, widened, notched, inverted
- Prominent U waves
Toxic effects
- QRS prolongation
- Various degrees of AV blocks or marked sinus bradycardia, sinus arrest or SA blocks
- Various Ventricular rhythms and sudden death

HYPERKALEMIA
- K < 7.5 mEq/L:
  - decreased amplitude of P-waves
  - wide QRS (Intraventricular conduction defect)
  - Tall, narrow, and peaked T-waves
- K > 7.5 mEq/L:
  - Absence of P-waves
  - ”sine wave” R-S-T pattern (sinoventricular rhythm)

HYPOKALEMIA
- ST depression. Decreased T-wave amplitude (or inversion),
- Prominent U-waves and P-waves
- Prolongation of the QRS duration
- Prolonged QT interval

HYPERCALCEMIA
- Short QT interval (short ST)

HYPOCALCEMIA
- Prolonged QT interval (long ST)

Prepared by Darwin Brown, PA-C and Charles Seelig, MD.
3/2003 update
CLINICAL ENTITIES THAT HAVE BEEN ASSOCIATED WITH ELEVATED C-TROPONIN-1 LEVELS

- Myocarditis
- Cardiomyopathy
- Congestive heart Failure
- Sepsis
- Pulmonary Embolism
- Rhabdomyolysis
- Chest Contusion
- Emboli caused by endocarditis
- Mural Thrombi
- Prosthetic valves
- Neoplasms
- Inflammatory processes, including viral infections such as with coxsackie B
- Radiation-induced coronary stenosis
- Congenital abnormalities in a coronary artery
- Hurler’s syndrome
- Homocystinuria
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Marathon runners
- Cocaine abusers
- MI
- Angina
- Cardiac Surgery

Specimens from patient who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies

References


“The impact of congestive heart failure in perioperative morbidity and mortality is often minimized. Currently 2.3* million Americans have CHF with 400,000 added each year. The mortality rate for CHF is between 15 to 60% with 200,000 deaths each year.”


* 5 million. 2006 American College of Cardiology
http://www.acc.org/media/patient/chd/chf/htm

Criteria for NYHA Functional Classification for CHF Patients* Functional Capacity

Class I
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea.

Class II
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.

Class III
Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.

Class IV
Unable to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency may be present even at rest. If any physical activity is undertaken, discomfort is increased.


Pathology—Unstable Angina

Clinical Definition:
1. New onset of angina occurring at rest or low levels of exercise.
   or
2. A sudden increase in frequency and severity of previously stable angina.
   or
3. Recurrent rest angina or an episode of prolonged ischemia pain without subsequent evidence of myocardial necrosis.

Apparently, the event initiating all acute ischemia syndromes is the development of plaque fissuring, fracture, ulceration, or rupture.

Unstable angina is to be differentiated from Prinzmetal’s angina, in that in the former, more severe underlying coronary artery disease is present, and vasospasm is just one (generally within a continuum) of the pathophysiological mechanisms promoting recurrent ischemia. In unstable angina, pain can be associated with ST segment elevation on the ECG (as in Prinzmetal’s), but exercise capacity would be preserved because of high-grade underlying coronary artery stenosis in one or more coronary vessels.
Natriuretic Peptides in Congestive Heart Failure

Three major natriuretic peptides are under study for use in the neurohumoral profiling in congestive heart failure. Atrial (A-type) natriuretic peptide (ANP) and BNP which are of myocardial cell origin and C-type natriuretic peptides which are of endothelial origin. BNP is secreted from the ventricles in response to volume expansion and pressure overload; some BNP is released from the atrial tissue. ANP major storage sites include both the atria and ventricles.

BNP levels are being used to assess clinical status and predict prognosis of patients in congestive heart failure. BNP levels correlate with hemodynamic parameters such as right atrial pressure (RAP), PCWP, and left ventricular end diastolic pressures. Studies have compared BNP measurements with echocardiogram as a reference diagnostic standard in appropriate patients with New York Heart Association classes I-IV heart failure.1

<table>
<thead>
<tr>
<th>NYHA CLASS</th>
<th>Mean ± SD (ng/L)</th>
<th>True Normal &lt;80</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>240±290</td>
<td>1-300</td>
</tr>
<tr>
<td>II</td>
<td>390±370</td>
<td>300-600</td>
</tr>
<tr>
<td>III</td>
<td>640±450</td>
<td>600-900</td>
</tr>
<tr>
<td>IV</td>
<td>820±440</td>
<td>&gt;900-1000</td>
</tr>
</tbody>
</table>

(UNMC Daniel Mathers, M.D., FACC)

Interpretation of Levels of BNP:

A. No CHF: 9 pg/ml (Median BNP)
B. CHF
   1. CHF Diagnosis: >100 pg/ml (standard cutoff)
   2. NYHA Class I CHF: Median BNP 83 pg/ml (49-137)
   3. NYHA Class II CHF: Median BNP 235 pg/ml (137-391)
   4. NYHA Class III CHF: Median BNP 459 pg/ml (200-871)
   5. NYHA Class IV CHF: Median BNP 1119 pg/ml (>728)
Causes of increased BNP level are congestive heart failure, left ventricular hypertrophy, cardiac inflammation (myocarditis, cardiac allograft rejection), Kawasaki disease, primary pulmonary hypertension, renal failure, ascitic cirrhosis, primary hyperaldosteronism, Cushing syndrome, Pulmonary embolism, increased C-Reactive Protein and septic shock.

Patients with lung disease may have higher levels of BNP than patients without lung disease in part because many patients with end stage pulmonary disorders have concomitant RV dysfunction another BNP trigger.

1
B-type natriuretic peptide (BNP, for CHF {Mar 2004; 121-6}
http://www.jr2.ox.ac.uk/bandolier/band121/b121-6.html

2
Family Practice notebook.com, a Family Medicine Resource
http://www.fpnotebook.com/CV140.htm

looksmart, Maisel, Alan S., Measuring BNP levels in the diagnosis and treatment of CHF: an evolving tool proves invaluable when time is of the essence
http://www.looksmart.com/
http://www.findarticles.com/
    Journal of Critical Illness>Nov, 2002

Reviewed and edited by:
Daniel Mathers, M.D., FACC
Cardiology
UNMC
<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Major cardiovascular manifestations</th>
<th>Major noncardiac abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heritable and Possibly Heritable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ellis-van Creveld</td>
<td>Single atrium or atrial septal defect</td>
<td>Chondrodystrophic dwarfism, nail dysphasia, polydactyly</td>
</tr>
<tr>
<td>TAR (thrombocytopenia-absent</td>
<td>Atrial septal defect, tetralogy of Fallot</td>
<td>Radial aplasia or hypoplasia, thrombocytopenia</td>
</tr>
<tr>
<td>radius)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holt-Oram</td>
<td>Atrial septal defect (other defects common)</td>
<td>Skeletal upper limb defect, hypoplasia of clavicles</td>
</tr>
<tr>
<td>Kartagener</td>
<td>Dextrocardia</td>
<td>Situs inversus, sinusitis, bronchiectasis</td>
</tr>
<tr>
<td>Laurence-Moon-Biedl</td>
<td>Variable defects</td>
<td>Retinal pigmentation, obesity, polydactyly</td>
</tr>
<tr>
<td>Noonan</td>
<td>Pulmonary valve dysplasia, cardiomyopathy (usually hypertrophic)</td>
<td>Webbed neck, pectus excavatum, cryptorchidism</td>
</tr>
<tr>
<td>Tuberous sclerosis</td>
<td>Rhabdomyoma, cardiomyopathy</td>
<td>Phakomatosis, bone lesions, hamartomatous skin lesions</td>
</tr>
<tr>
<td>Multiple lentigines (leopard)</td>
<td>Pulmonic stenosis</td>
<td>Basal cell nevi, broad facies, rib anomalies</td>
</tr>
<tr>
<td>syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubenstein-Taybi</td>
<td>Patent ductus arteriosus (others)</td>
<td>Broad thumbs and toes, hypoplastic maxilla, slanted palpebral fissures</td>
</tr>
<tr>
<td>Familial deafness</td>
<td>Arrhythmias, sudden death</td>
<td>Sensorineural deafness</td>
</tr>
<tr>
<td>Osler-Rendu-Weber</td>
<td>Arteriovenous fistulas (lung, liver, mucous membranes)</td>
<td>Multiple telangiectasia</td>
</tr>
<tr>
<td>Apert</td>
<td>Ventricular septal defect</td>
<td>Craniosynostosis, midfacial hypoplasia, syndactyly</td>
</tr>
<tr>
<td>Incontinentia pigmenti</td>
<td>Patent ductus arteriosus</td>
<td>Irregular pigmented skin lesions, patchy alopecia, hypodontia</td>
</tr>
<tr>
<td>Alagille (arteriohepatic</td>
<td>Peripheral pulmonic stenosis, pulmonic stenosis</td>
<td>Biliary hypoplasia, vertebral anomalies, prominent forehead, deep-set eyes</td>
</tr>
<tr>
<td>dysplasia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DiGeorge</td>
<td>Interrupted aortic arch, tetralogy of Fallot, truncus arteriosus</td>
<td>Thymic hypoplasia or aplasia, parathyroid aplasia or hypoplasia, ear anomalies</td>
</tr>
<tr>
<td>Friedreich’s ataxia</td>
<td>Cardiomyopathy and conduction defects</td>
<td>Ataxia, speech defect, degeneration of spinal cord dorsal columns</td>
</tr>
<tr>
<td>Muscular dystrophy</td>
<td>Cardiomyopathy</td>
<td>Pseudohypertrophy of calf muscles, weakness of trunk and proximal limb muscles</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td>Cor pulmonale</td>
<td>Pancreatic insufficiency, malabsorption, chronic lung disease</td>
</tr>
<tr>
<td>Sickle cell anemia</td>
<td>Cardiomyopathy, mitral regurgitation</td>
<td>Hemoglobin SS</td>
</tr>
<tr>
<td>Conradi-Hünermann</td>
<td>Ventricular septal defect, patent ductus arteriosus</td>
<td>Asymmetric limb shortness, early punctate mineralization, large skin pores</td>
</tr>
</tbody>
</table>
**Cachectic dwarfism, retinal pigment abnormalities, photosensitivity dermatitis**

Premature aging, alopecia, atrophy of subcutaneous fat, skeletal hypoplasia

<table>
<thead>
<tr>
<th>Connective Tissue Disorders</th>
<th>Accelerated atherosclerosis</th>
<th>Generalized disruption of elastic fibers, diminished skin resilience, hernias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutis laxa</td>
<td>Peripheral pulmonic stenosis</td>
<td>Hyperextensible joints, hyperelastic and friable skin</td>
</tr>
<tr>
<td>Ehlers-Danlos</td>
<td>Arterial dilatation and rupture, mitral regurgitation</td>
<td>Gracile habitus, arachnodactyly with hyperextensibility, lens subluxation</td>
</tr>
<tr>
<td>Marfan</td>
<td>Aortic dilatation, aortic and mitral incompetence</td>
<td>Fragile bones, blue sclera</td>
</tr>
<tr>
<td>Osteogenesis imperfecta</td>
<td>Aortic incompetence</td>
<td>Degeneration of elastic fibers in skin, retinal angioid streaks</td>
</tr>
<tr>
<td>Pseudoxanthoma elasticum</td>
<td>Peripheral and coronary arterial disease</td>
<td></td>
</tr>
</tbody>
</table>

**INBORN ERRORS OF METABOLISM**

<table>
<thead>
<tr>
<th>Pompe’s disease</th>
<th>Glycogen storage disease of heart</th>
<th>Acid maltase deficiency, muscular weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homocystinuria</td>
<td>Aortic and pulmonary arterial dilatation, intravascular thrombosis</td>
<td>Cystathionine synthetase deficiency, lens subluxation, osteoporosis</td>
</tr>
<tr>
<td>Mucopolysaccharidosis:</td>
<td>Multivalvular and coronary and great artery disease, cardiomyopathy</td>
<td>Hurler: Deficiency of α-L-iduronidase, corneal clouding, coarse features, growth and mental retardation. Hunter: Deficiency of L-iduranosulfate sulfatase, coarse facies, clear cornea, growth and mental retardation</td>
</tr>
<tr>
<td>Hurler, Hunter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morquio, Scheie, Maroteaux-Lamy</td>
<td>Aortic incompetence</td>
<td>Morquio: Deficiency of N-acetylhexosamine sulfate sulfatase, cloudy cornea, normal intelligence, severe bony changes involving vertebrae and epiphyses. Scheie: Deficiency of α-iduronidase, cloudy cornea, normal intelligence, peculiar facies. Maroteaux-Lamy: Deficiency of arylsulfatase B, cloudy cornea, osseous changes, normal intelligence</td>
</tr>
</tbody>
</table>

**CHROMOSOMAL ABNORMALITIES**

<table>
<thead>
<tr>
<th>Trisomy 21 (Down’s syndrome)</th>
<th>Endocardial cushion defect, atrial or ventricular septal defect, tetralogy of Fallot</th>
<th>Hypotonia, hyperextensible joints, mongoloid facies, mental retardation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisomy 13 (D)</td>
<td>Ventricular septal defect, patent ductus arteriosus, double-outlet right ventricle</td>
<td>Single midline intracerebral ventricle with midfacial defects, polydactyly, nail changes, mental retardation</td>
</tr>
<tr>
<td>Condition</td>
<td>Presentation</td>
<td>Disorder</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Trisomy 18 (E)</td>
<td>Congenital polyvalvular dysplasia, ventricular septal defect, patent ductus</td>
<td>Clenched hand, short sternum, low-arch dermal-ridge pattern on fingertips, mental retardation</td>
</tr>
<tr>
<td></td>
<td>arteriosus</td>
<td></td>
</tr>
<tr>
<td>Cri-du-chat (short-arm deletion-5)</td>
<td>Ventricular septal defect</td>
<td>Cat cry, microcephaly, antimongoloid slant of palpebral fissures, mental retardation</td>
</tr>
<tr>
<td>XO (Turner)</td>
<td>Coarctation of aorta, bicuspid aortic valve</td>
<td>Short female, broad chest, lymphedema, webbed neck</td>
</tr>
<tr>
<td>XXXY and XXXXX</td>
<td>Patient ductus arteriosus</td>
<td>XXXY: hypogenitalism, mental retardation, radial-ulnar synostosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XXXXX: small hands, incurring of fifth fingers, mental retardation</td>
</tr>
</tbody>
</table>

### Sporadic Disorders

<table>
<thead>
<tr>
<th>Association</th>
<th>Condition</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>VATER association</td>
<td>Ventricular septal defect</td>
<td>Vertebral anomalies, anal atresia, tracheoesophageal fistula, radial and renal anomalies</td>
</tr>
<tr>
<td>CHARGE association</td>
<td>Tetralogy of Fallot (other defects common)</td>
<td>Colobomas, choanal atresia, mental and growth deficiency, genital and ear anomalies</td>
</tr>
<tr>
<td>Williams</td>
<td>Supravalvular aortic stenosis, peripheral pulmonic stenosis</td>
<td>Mental deficiency, “elfin” facies, loquacious personality, hoarse voice</td>
</tr>
<tr>
<td>Cornelia de Lange</td>
<td>Ventricular septal defect</td>
<td>Micromelia, synophrys, mental and growth deficiency</td>
</tr>
<tr>
<td>Shprintzen (velocardiofacial)</td>
<td>Ventricular septal defect, tetralogy of Fallot, right aortic arch</td>
<td>Cleft palate, prominent nose, slender hands, learning disability</td>
</tr>
</tbody>
</table>

### Teratogenic Disorders

<table>
<thead>
<tr>
<th>Condition</th>
<th>Presentation</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rubella</td>
<td>Patent ductus arteriosus, pulmonic valvular and/or arterial stenosis, atrial septal defect</td>
<td>Cataracts, deafness, microcephaly</td>
</tr>
<tr>
<td>Alcohol-induced</td>
<td>Ventricular septal defect (other defects)</td>
<td>Microcephaly, growth and mental deficiency, short palpebral fissures, smooth philtrum, thin upper lip</td>
</tr>
<tr>
<td>Phenytoin-induced</td>
<td>Pulmonic stenosis, aortic stenosis, coarctation, patient ductus arteriosus</td>
<td>Hypertelorism, growth and mental deficiency, short phalanges, bowed upper lip</td>
</tr>
<tr>
<td>Thalidomide-induced</td>
<td>Variable</td>
<td>Phocomelia</td>
</tr>
<tr>
<td>Lithium-induced</td>
<td>Ebstein’s anomaly, tricuspid atresia</td>
<td>None</td>
</tr>
</tbody>
</table>

37
**Down’s Syndrome**

*Common Surgical Procedures:*
- cardiac malformations
- congenital duodenal obstructions
- strabismus
- congenital cataract or glaucoma
- kyphoscoliosis
- dental care

*Congenital Heart Disease (40–50% DS)*
- tetralogy of Fallot, 8%
- cardiac cushion defect, 40–50%
- atrioventricularis communis
- persistent PDA, 12%

*DS patients may have:*
- immunological deficiency
- adrenal response to ACTH may be subnormal
- thyroid hypofunction
- leukemia
- epilepsy or senile dementia

*Skeletal abnormalities associated with DS*
- scoliosis
- 15–20% instability of the atlantoaxial joints (asymptomatic in the majority of patients)
- hypoplastic facial bones
- maxilla and mandible are small, resulting in protruding tongue—unusually large
- high arched palate
- abnormal dentition: numbers, shape, location
- narrow nasopharynx
- tonsils and adenoids that are large
- larynx may be small
- increased incidence of subglottic stenosis
- increased frequency of laryngospasm
- chronic upper airway obstruction which may lead to arterial hypoxemia
- microcephaly

The endotracheal tube required may need to be smaller than predicted by age or height.

*Pre-op evaluation should include:*
- lateral neck in flexion and extension to assess atlantoaxial instability
- ECHO
  - patient with known cardiac lesion or audible murmur >20 years old who has not had an ECHO within the last 3–5 yr (results of ECHO must be available at time of pre-op workup)
- SBE coverage
- Consider need for possible
  - steroids
  - thyroid studies

Patient does not respond to antihypertensive therapy

Does the patient take oral contraceptives, cocaine, sympathomimetics, corticosteroids, mineralocorticoids, or vasopressin?

Are serum potassium levels <3.5 mEq/L?

No

Is the patient older than 30?

Yes

Treat hypertension

No

Adequate control?

Yes

Essential hypertension

No

Secondary hypertension

Check serum catecholamine levels

>1,000 ng/L

Pheochromocytoma

No

800-1,000 ng/L

Perform clonidine suppression test

Suppressed?

No

Yes

Essential hypertension

>800 ng/L

is captopril challenge positive?

No

Are plasma renin levels elevated?

Yes

Renal artery stenosis

Yes

is renal angiography positive?

No

Essential hypertension

Primary hyperaldosteronism

Drug-induced hypertension

Are urinary aldosterone levels >14.0 μg/24 h?

Yes


Figure 1 Does the patient have truly resistant hypertension?
The Five H’s: Hypertension, Hypermetabolism, Hyperhydrosis, Headache, & Hyperglycemia

In 5% of patients with hypertension there is a secondary cause such as renovascular hypertension, primary aldosteronism, and pheochromocytoma. Approximately 36,000 patients in the U.S., or from 0.09% to 2.2% of all patients with sustained hypertension, have a pheochromocytoma:
- 90% are found in the adrenal medulla (R > L), and about 10% bilaterally.
- a small percentage are found in extra-adrenal sites (especially in children).
- primarily found within the ages of 30–50 years old, with approximately 1/3 of the cases occurring in children (males > females). 10% family history for pheochromocytoma.
- associated with multiple endocrine neoplasia (MEN).

Table 1. Manifestations of Multiple Endocrine Neoplasia (MEN)

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN type IIa (Sipple Syndrome)</td>
<td>Medullary thyroid cancer, Parathyroid adenoma, Pheochromocytoma</td>
</tr>
<tr>
<td>MEN type IIB</td>
<td>Medullary thyroid cancer, Mucosal adenomas, Marfan appearance, Pheochromocytoma</td>
</tr>
<tr>
<td>von Hippel-Lindau Syndrome</td>
<td>Hemangioblastoma involving the central nervous system, Pheochromocytoma</td>
</tr>
</tbody>
</table>

Table 2. Features of Pheochromocytoma

Severe headache  
Palpitations  
Weakness, weight loss  
Tachycardia (rarely brady)  
Hypertension, sustained or paroxysmal  
Association conditions such as neurofibromatosis, thyroid swelling  
Episodic sweating  
Anxiety, tremulousness  
Pallor (rarely, flushing)  
Orthostatic hypotension  
Paradoxical blood pressure response to drugs, anesthesia  

More than 95% of patients have HA’s, hyperhidrosis, and palpitations. FLUSHING IS RARE in pheochromocytoma.
Table 3. Differential Diagnosis of pheo’s
Anxiety, psychosis
Paroxysmal cardiac arrhythmias
Autonomic insufficiency
Hyperdynamic circulatory states
Migraine, cluster headaches
Coronary artery disease, heart disease
Labile essential hypertension
Autonomic hyperreflexia in quadriplegic persons
Hypertension induced by drugs or drug/food interaction
Hyperthyroidism
Diabetes
Hypoglycemia
Eclampsia
Neuroblastoma
Lead intoxication
Porphyria
Carcinoid
Hypertension from sudden drug withdrawal

Triggering Factors
Exercise, vigorous abdominal palpations, gravid uterus, bladder distention, constipation, trauma, drugs: tricyclic antidepressants, phenothiazines, histamines, glucagon, epinephrine, β-blockers, angiotensin II analogs, metoclopramide, nicotine.

Nearly 50% of deaths due to unsuspected pheochromocytomas occur during anesthesia and surgery or parturition. Time of significant intra-operative concerns: 1) during intubation, 2) during manipulation of tumor, 3) after ligation of the tumor’s venous drainage.

Work-ups: metanephrine levels; VMA; clonidine suppression test; CXR to include oblique, CT scan, adrenal scintigraphy, arteriography, and venous sampling.

Patients should be treated 7–10 days prior to procedures with drugs such as phenoxybenzamine or metryzosine and generally given IV fluids 2–3 days prior to surgery.

Ischemic Heart Disease

Approximately one third of the 25 million patients in the U.S. who are undergoing surgery each year are at high risk for ischemic heart disease (IHD). Since a patient may be asymptomatic despite 50–70% stenosis of a major coronary artery, acute myocardial infarction and sudden death may be the first indication of IHD (more than 50% of victims of sudden death have unexpected IHD).

Risk Status on Presence of CHD Risk Factors Other than LDL-cholesterol

Positive Risk Factors

1. Age
   Male ≥45 years
   Female ≥55 years or premature menopause without estrogen replacement therapy
2. Family history of premature CHD
   Definite myocardial infarction or sudden death before 55 years of age in father or other male first degree relative, or before 65 years of age in mother or other female first degree relative.
3. Current cigarette smoking
   It is estimated that cigarette smoking is responsible for 30% of the 500,000 annual fatalities attributed to IHD. The addition of the risk factor of cigarette smoking is equivalent to increasing plasma cholesterol concentration 50–100 mg/dl.
   “According the American Cancer Society, within just 20 minutes of your last cigarette, your blood pressure and pulse rate drop to normal levels. Within 48 hours, your ability to smell and taste are enhanced. After 2 to 12 weeks, circulation improves and lung function increases by up to 30%. Breathing becomes noticeably easier. Within a year, the risk of heart disease drops to half that of a current smoker. At the 5-year mark, the death rate from lung cancer for the average former pack-a-day smoker decreases by almost 50%. By 10 years, the death rate from lung cancer is similar to that of nonsmokers. At 15 years, the risk of heart disease is the same as that of a nonsmoker.”
4. Hypertension
   ≥140/90 mm Hg or on antihypertensive medications
   “Commonly, hypertension on admission to the hospital is regarded as a “normal” response to the stress of hospital admission. However, this group of patients may represent an untreated or inadequately managed subset of hypertensive patients. A study examining this problem revealed that these patients generated the highest mean arterial BP (MAP) in response to laryngoscopy and intubation. In addition, myocardial ischemia was observed and 75% of the patients in this group required vasodilator therapy. In contrast,
those patients with normal admission BP, or adequately treated hypertension, had an uneventful per-induction course.

In the perioperative period, uncontrolled or poorly controlled hypertension is associated with an increased incidence of ischemia, myocardial infarction, dysrhythmias, and stroke. Adequate preoperative treatment is associated with a reduced incidence of serious cardiovascular complications.”

**Classifying Blood Pressure in Adults**

<table>
<thead>
<tr>
<th>Category</th>
<th>Blood pressure (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Systolic</td>
</tr>
<tr>
<td>Normal*</td>
<td>&lt;130</td>
</tr>
<tr>
<td>High normal</td>
<td>130–139</td>
</tr>
<tr>
<td>Hypertension†</td>
<td></td>
</tr>
<tr>
<td>Stage 1 (mild)</td>
<td>140–159</td>
</tr>
<tr>
<td>Stage 2 (moderate)</td>
<td>160–179</td>
</tr>
<tr>
<td>Stage 3 (severe)</td>
<td>180–209</td>
</tr>
<tr>
<td>Stage 4 (very severe)</td>
<td>&gt;210</td>
</tr>
</tbody>
</table>

*Regarding cardiovascular risk, optimal BP is a systolic measurement of <120 mm Hg and a diastolic measurement of <80 mm Hg. Unusually low readings should, however, be evaluated for clinical significance.

†Based on the average of 2 or more readings that have been taken at each of two or more visits after initial screening.

NOTE: Adult refers to persons 18 years and older. Also, this classification is limited to persons who are neither taking antihypertensive drugs nor acutely ill. To determine BP status when systolic and diastolic BP fall into different categories, assign the patient to the category in which the higher measurement falls (e.g., 160/ mm Hg is stage 2; 180–120 mm Hg is stage 4). Isolated systolic hypertension (ISH) is defined as systolic BP of >140 mm Hg and diastolic BP <90 mm Hg (e.g., 170/85 mm Hg is classified as stage 2 ISH).

In addition to classifying stages of hypertension based on average BP levels, the clinician should specify the presence or absence of target-organ disease and other risk factors. A patient who has diabetes, BP of 142/94 mm Hg, and left ventricular hypertrophy, for example, should be classified as stage 1 hypertension with target-organ disease (left ventricular hypertrophy) and with an additional major risk factor (diabetes). This specificity is important for calculating risk and for management.

Stage 1 Hypertension: Treatment Considerations and Realities. JAAPA, January 1996, pp. 28–38.
Causes of Secondary Hypertension

I. Renal disease
   A. Parenchymal disease
      1. Chronic pyelonephritis
      2. Glomerulonephritis (acute and chronic)
      3. Nephrolithiasis
      4. Polycystic kidney disease
   B. Renal artery stenosis (renovascular hypertension)
   C. Renin-producing tumors

II. Endocrinologic diseases
   A. Primary hyperaldosteronism
   B. Cushing’s syndrome or disease
   C. Pheochromocytoma
   D. Hyperthyroidism
   E. Congenital or hereditary adrenogenital syndromes
   F. Myxedema
   G. Acromegaly
   H. Hyperparathyroidism

III. Coarctation of the aorta

IV. Substance abuse
   A. Cocaine
   B. Alcohol
   C. Other stimulants (amphetamine)

V. Drugs
   A. Oral contraceptive agents
   B. Phenylpropanolamine phenylephrine

VI. Miscellaneous
   A. Elevated intracranial pressure (acute)
   B. Fever
   C. Pregnancy
   D. Acute stress or anxiety
   E. Other

The estimated decrease in the risk of myocardial infarction is 2–3% for every reduction of 1 mm Hg in the diastolic blood pressure.

5. Low HDL cholesterol $<35$ mg/dl
   Total cholesterol $>200$ mg/dl

   About one third of the adults in the U.S. have hypercholesterolemia. It is estimated that maintaining plasma cholesterol below 200 mm/dl would decrease the incidence of IHD 30–50% in persons younger than 65 years of age. Alternatively, a 1% decrease in a patient’s total plasma cholesterol concentration yields a 2–3% reduction in the risk of IHD.

6. Diabetes mellitus
   Prominent risk factor for development of IHD
Negative Risk Factors
High HDL-cholesterol (≥60 mg/dl)

“A postoperative MI is a lethal lesion with a >50% mortality rate.”


“Left ventricular ejection fraction,…as determined by MUGA Scan, has been shown to be an important predictor of survival in patients with myocardial infarction and congestive heart failure” (who are undergoing non-cardiac surgery).

<table>
<thead>
<tr>
<th>LVEF</th>
<th>Mortality Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;55%</td>
<td>2.2%</td>
</tr>
<tr>
<td>35–54%</td>
<td>5.4%</td>
</tr>
<tr>
<td>&lt;35%</td>
<td>19.5%</td>
</tr>
</tbody>
</table>

For LVEF of <50% or >70%, the cardiac complication rate is 58%, as compared to 12% in those with normal ejection fractions.

Preoperative Medicine, 2nd ed. Goldman, Brown. The Surgical Patient with Congestive Heart Failure, Howard J. Eiser.
I. ECHOCARDIOGRAPHY

A. M-Mode Echocardiography

The M-mode echo, which provides an "ice pick" view of the heart, is important in the evaluation of certain cardiac conditions and functions, particularly in the measurement of dimensions and timing. An M-mode echo through three important structures of the left side of the heart is illustrated in Fig 2-1.

1. Applications of the M-mode echo
   a. Measurement of the dimensions of cardiac chambers and vessels and the thickness of the ventricular septum and free walls.
   b. LV systolic function (e.g., fractional shortening, ejection fraction).
   c. Study of the motion of valves (e.g., MVP, MS, pulmonary hypertension) and the interventricular septum.
   d. Detection of pericardial fluid.

2. Normal M-mode echo values (See Appendix, Tables A-3, A-4)

3. LV Function (see Table A-4)
   a. Fractional shortening (FS) of the LV is as follows:

   \[ FS(\%) = \frac{Dd - Ds}{Dd} \times 100, \]

   where Dd is end-diastolic dimension and Ds is end-systolic dimension.
FIG. 2-1.

Cross-sectional view of the left side of the heart along the long axis (top) through which ice pick views of the M-mode echo recordings are made (bottom).  

a. RV dimension.  
b. LV diastolic dimension (Dd).  
c. thickness of ventricular septum.  
d. thickness of posterior free wall.  
e. LA dimension.  
f. aortic dimension.  
g. LV systolic dimension (Ds).  

AMV, anterior mitral valve.  PMV, posterior mitral valve.  LVET, LV ejection time.  PEP, pre-ejection period.  (From Park MK: Pediatric Cardiology for Practitioners, ed 3. St. Louis, Mosby, 1995.)

Normal FS is 36% (28% to 44%, 95% CI).  
b. Ejection fraction (EF) is obtained by this formula:  

\[
EF (%) = \frac{(Dd)^3 - (Ds)^3}{(Dd)^3} \times 100.
\]

Normal EF is 74% (64% to 83%, 95% CI).  
c. Systolic time intervals
**Prophylaxis Guidelines—Endocarditis**

**Erythromycin for Bacterial Endocarditis Prophylaxis: Then and Now**

- **In 1994**, the American Heart Association issued recommendations for antibiotic prophylaxis for patients who are prone to bacterial endocarditis. For amoxicillin/penicillin-allergic patients, the Heart Association recommended:

  | Erythromycin ethylsuccinate 800 mg or erythromycin stearate 1.0 g orally 2 hours before a procedure; then on-half the dose 6 hours after the initial dose. |
  | Clindamycin 300 mg orally 1 hour before a procedure and 150 mg 6 hours after initial dose. |

**Problem #1:** There was confusion over the Heart Association’s recommendations. The Association said to use 1 g erythromycin stearate, or if you’re using the ethylsuccinate salt, they say to give 800 mg. Pharmacists generally agree that 250 mg of stearate is roughly equivalent to 500 mg of the ethylsuccinate. So, 1 g of stearate is roughly equivalent to 1600 mg of ethylsuccinate... not 800 mg as recommended by the Heart Association. While these doses of erythromycin aren’t considered equivalent, they provide adequate antibiotic concentrations.

**Problem #2:** Erythromycin can cause GI upset.

- **In 1997**, the Heart Association issued new guidelines. Erythromycin is no longer recommended for the amoxicillin/penicillin-allergic patient. Instead, the Heart Association recommends:

  | A single dose of clindamycin 600 mg, azithromycin 500 mg, clarithromycin 500 mg, cephalexin 2 g or cefadroxil 2 g for adults. |

But if the patient and physician are comfortable using the old erythromycin regimen, they can continue to do so; but the new regimen is considered effective and has fewer side effects.

To help you keep track of who should receive prophylaxis for bacterial endocarditis, what procedures are risky and what regimens are recommended, we have attached some tables reprinted with permission from the American Heart Association.
Cardiac Conditions For Which Prophylaxis Is Or Is Not Recommended

**Endocarditis Prophylaxis Recommended**

**High Risk Category**
- Prosthetic cardiac valves, including bioprosthetic and homograft valves
- Previous bacterial endocarditis
- Complex cyanotic congenital heart disease (e.g. single ventricle states, transposition of the great arteries, tetralogy of Fallot)
- Surgically constructed systemic-pulmonary shunts or conduits

**Moderate Risk Category**
- Most other congenital cardiac malformations (other than above and below)
- Acquired valvar dysfunction (e.g. rheumatic heart disease)
- Hypertrophic cardiomyopathy
- Mitral valve prolapse with valvar regurgitation and/or thickened leaflets

**Endocarditis Prophylaxis Not Recommended**

**Negligible Risk Category (No Greater than the General Population)**
- Isolated secundum atrial septal defect
- Surgical repair of atrial septal defect, ventricular septal defect, or patent ductus arteriosus (without residual beyond 6 mo)
- Previous coronary artery bypass graft surgery
- Mitral valve prolapse without valvar regurgitation
- Physiologic, functional, or innocent heart murmurs
- Previous Kawasaki disease without valvar dysfunction
- Previous rheumatic fever without valvar dysfunction
- Cardiac pacemaker (intravascular and epicardial) and implanted defibrillators

**Dental Procedures For Which Prophylaxis Is Or Is Not Recommended**

**Endocarditis Prophylaxis Recommended**

*Dental extractions
Periodontal procedures including surger, scaling and root planing, probing, recall maintenance
Dental implant placement and reimplantation of avulsed teeth
Endodontic (root canal) instrumentaion or surgery only beyond the apex
Subgingival placement of antiobiotic fibers/strips
Initial placement of orthodontic bands but not brackets
Intraligamentary local anesthetic injections
Prophylactic cleaning of teeth or implants where bleeding is anticipated
Endocarditis Prophylaxis Not Recommended

Restorative dentistry* (operative and prosthodontic) with/without retraction cord#
Local anesthetic infections (nonintraglamentary)
Intracanal endodontic treatment; post placement and buildup
Placement of rubber dams
Postoperative suture removal
Placement of removable prosthodontic/orthodontic appliances
Taking of oral impressions
Taking of oral radiographs
Fluoride treatments
Orthodontic appliance adjustment
Shedding of primary teeth

* Prophylaxis is recommended for patients with high and moderate risk cardiac conditions.
* This includes restoration of decayed teeth (filling cavities) and replacement of missing teeth.
# Clinical judgement may indicate antibiotic use in selected circumstances that may create significant bleeding.

Other Procedures For Which Prophylaxis Is Or Is Not Recommended

Endocarditis Prophylaxis Recommended
Respirator Tract
   Tonsillectomy and/or adenoidectomy
   Surgical operations that involve respiratory mucosa
   Bronchoscopy with a rigid bronchoscope
Genitourinary Tract
   Prostatic surgery
   Cystoscopy
   Urethral dilation
Gastrointestinal Tract*
   Sclerotherapy for esophageal varices
   Esophageal stricture dilation
   Endoscopic retrograde cholangiography with billiary obstruction
   Billiary tract surgery
   Surgical operations that involve intestinal mucosa

Endocarditis Prophylaxis Not Recommended
Respiratory Tract
   Endotracheal intubation
   Bronchoscopy with flexible bronchoscope, with or without biopsy#
   Tympanostomy tube insertion
Gastrointestinal Tract
   Transophageal echocardiography#
   Endoscopy with or without gastrointestinal biopsy#
Genitourinary Tract

Vaginal hysterectomy#

Vaginal delivery#

Cesarean section

In uninfected tissue:

- urethral catheterization
- Uterine dilatation and curettage
- therapeutic abortion
- sterilization procedures
- insertion or removal of intrauterine devices

Other

- Cardiac catheterization, including balloon angioplasty
- Implantation of cardiac pacemakers, implanted defibrillators, and coronary stents
- Incision of biopsy of surgically scrubbed skin
- Circumcision

* Prophylaxis is recommended for high-risk patients; optional for medium-risk patients.

# Prophylaxis is optional for high-risk patients.
### Prophylactic Regimens For Dental, Oral, Respiratory Tract, Or Esophageal Procedures
(No Follow-Up Dose Recommended)

<table>
<thead>
<tr>
<th>Situation</th>
<th>Agent</th>
<th>Regimen#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard general prophylaxis</td>
<td>Amoxicillin</td>
<td>Adults: 2.0 g; Children: 50 mg/kg PO 1 hour before procedure</td>
</tr>
<tr>
<td>Unable to take oral medications</td>
<td>Ampicillin</td>
<td>Adults: 2.0 g IM or IV; Children: 50 mg/kg IM or IV within 30 minutes before procedure</td>
</tr>
<tr>
<td>Penicillin-allergic</td>
<td>Clindamycin OR Cephalexin* OR Cefadroxil* OR Azithromycin or Clarithromycin</td>
<td>Adults: 600 mg; Children: 20 mg/kg PO 1 hour before procedure</td>
</tr>
<tr>
<td>Penicillin-allergic and unable to take oral medications</td>
<td>Clindamycin OR Cefazolin*</td>
<td>Adults: 600 mg; Children: 20 mg/kg IV within 30 minutes before procedure</td>
</tr>
</tbody>
</table>

# Total children’s dose should not exceed adult dose.

* Cephalosporins should not be used in individuals with immediate type hypersensitivity reaction (urticaria, angioedema, or anaphylaxis) to penicillins.

### Prophylactic Regimens For Genitourinary/Gastrointestinal (Excluding Esophageal) Procedures

<table>
<thead>
<tr>
<th>Situation</th>
<th>Agent(s)*</th>
<th>Regimen#</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-risk patients</td>
<td>Ampicillin plus Gentamicin</td>
<td>Adults: ampicillin 2.0 g IM/IV plus gentamicin 1.5 mg/kg (not to exceed 120 mg) within 30 min of starting the procedure. Six hours later, ampicillin 1 g IM/IV or amoxicillin 1 g PO. Children: ampicillin 50 mg/kg IM or IV (not to exceed 2.0 gm) plus gentamicin 1.5 mg/kg within 30 minutes of starting the procedure. Six hours later, ampicillin 25 mg/kg IM/IV or amoxicillin 25 mg/kg PO.</td>
</tr>
<tr>
<td>High-risk patients allergic to ampicillin/amoxicillin</td>
<td>Vancomycin plus Gentamicin</td>
<td>Adults: vancomycin 1.0 g IV over 1-2 hours plus gentamicin 1.5 mg/kg IV/IM (not to exceed 120 mg). Complete injection/infusion within 30 minutes of starting the procedure. Children: vancomycin, 20 mg per kg IV over on to two hours, plus gentamicin, 1.5 mg per kg IV or IM; injection or infusion should be completed within 30 minutes of starting the procedure.*</td>
</tr>
<tr>
<td>Moderate-risk patients</td>
<td>Amoxicillin OR Ampicillin</td>
<td>Adults: amoxicillin 2.0 gm PO 1 hour before procedure, OR Ampicillin 2.0 gm IM/IV within 30 minutes of starting the procedure Children: amoxicillin 50 mg per kg orally one hour before the procedure, OR ampicillin, 50 mg per kg IM or IV within 30 minutes of starting the procedure</td>
</tr>
<tr>
<td>Moderate-risk patients allergic to ampicillin/amoxicillin</td>
<td>Vancomycin</td>
<td>Adults: vancomycin 1.0 g IV over 1-2 hours. Complete infusion within 30 minutes of starting the procedure. Children: vancomycin 20 mg/kg IV over 1-2 hours. Complete infusion within 30 minutes of starting the procedure.</td>
</tr>
</tbody>
</table>

# Total children’s dose should not exceed adult dose.

* No second dose of vancomycin or gentamicin is recommended.
**Nebraska Health System/University of Nebraska Cardiac Risk Stratification**

Based on the American College of Cardiology/American Heart Association Guidelines

Patient to Undergo Surgery → Emergency Surgery → To Operating Room

- **≤4 METs**: ADLs (eat, bathe, dress), walk 1-2 blocks on level ground @ 2-3 mph/walk indoors around house
- **> or = 4 METs**: Climbing stairs, walking 4 mph, golfing, bowling, dancing, gardening

**Intermediate risk**: carotid endarterectomy, Head and neck surgery, intraperitoneal, intrathoracic, orthopedic, prostate

**High risk**: Aortic or other major vascular, prolonged procedures with large fluid shifts and/or blood loss

Those patients undergoing intermediate or high risk operations may be candidates for prophylactic perioperative beta blockade

---

**Risk Stratification**

---

**Major Clinical Predictors**

Unstable Angina
Acute Congestive Heart Failure
Recent Acute Myocardial Infarction
Severe Aortic Stenosis/Valvular Dz

- **Yes** → Cardiology Consult +/- Cardiac Catheterization
  - **Abnormal** → To OR
  - **Normal or Adequate** → Cardiology Consult +/- Cardiac Catheterization

---

**Intermediate Clinical Predictors**

One or More Risk Factors
History of MI
Stable Mild Angina
History of Congestive Heart Failure
Diabetes Mellitus
Renal Insufficiency

- **No**
- **<4 METs** → Non-invasive testing
- **> or = 4 METs** → Intermediate Risk

---

**No/Minor Clinical Predictors**

Uncontrolled HTN
Abnormal ECG
Rhythm other than sinus
Low functional capacity
History of/ current smoker
History of stroke
Age >70yr

- **Yes** → High Risk → Non-invasive testing
  - **Normal or Adequate** → To OR
- **No** → Low or Intermediate
  - **<4 METs** → To OR
  - **> or = 4 METs** → To OR

---

**Activity Level:**
- **<4 Mets**
- **≥ or = 4 Mets**

**Anticipated Procedure:**
- High Risk
- Intermediate Risk
- Low Risk

---

<table>
<thead>
<tr>
<th>Major Clinical Predictors</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermediate Clinical Predictors</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Minor Clinical Predictors</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
The Nebraska Medical Center: Prophylactic Perioperative Beta Blockade (PPBB) Protocol and Cardiac Risk Stratification

The following guidelines are basic recommendations and are not intended as absolute or standard requirements. Practice guidelines should be modified based on clinical needs and individual practice to ensure highest quality of care.

- **All patients scheduled for elective non-cardiac surgery (intermediate and high risk*) requiring general or regional anesthesia and a hospital stay qualify**
  - Emergency surgery and hemodynamically unstable patients assessed on an individual basis

- **PPBB should be considered for patients with**
  - Known coronary artery disease
  - Atherosclerotic vascular disease
  - Diabetes
  - Any two of the following: Age≥65, HTN, hyperlipidemia, current smoker

- **PPBB may be contraindicated in the following**
  - Sensitivity to Beta Blockers
  - Congestive Heart Failure (LVEF<30%)
  - Active Bronchospasm
  - Second or Third degree heart block
  - Systolic BP<100mmHg or HR<50 bpm
  - C-Section

- **Drug Choice:** Atenolol or Metoprolol may be used. If the patient is previously on another beta blocker, it is unnecessary to change to a Beta-1 selective drug. However, the dosage should be adjusted to keep HR<70 bpm perioperatively.

- **PPBB initiation:** **Target HR:** >50 and <70 bpm
  - **Preoperatively in clinic:** If HR≥60 and SBP≥100mmHg, begin metoprolol (25-50mg PO q 12h) or atenolol (50-100mg PO qd) several days before surgery.
  - **Immediately Preop:** If HR>70 and SBP>100mmHg, metoprolol 2.5-5.0mg IV can be given every 10 minutes to maintain HR<70 and SBP<100mmHg.
  - **During surgery:** If HR>70 and SBP>100mmHg, metoprolol 2.5-5.0mg IV can be given every 10 minutes to maintain HR<70 and SBP<100mmHg. Alternatively, esmolol infusion may be titrated to maintain HR<70.
  - **PACU or ICU:** If HR>70 and SBP>100mmHg, metoprolol 2.5-5.0mg IV can be given every 10 minutes to maintain HR<70 and SBP<100mmHg. Consider utilizing standard orders.
  - **Postoperative:** Utilize standard orders for both IV and PO dosing.
  - **Discharge:** **Oral Beta Blocker therapy should be continued for at least 7 days postoperatively.**
    - Goal HR<70 and SBP>100
    - Patients with a history of coronary artery disease may benefit from indefinite Beta-Blocker therapy.

*Intermediate risk:* Carotid endarterectomy, Head and neck surgery, intraperitoneal, intrathoracic, orthopedic, prostatectomy

**High risk:** Aortic or other major vascular, prolonged procedures with large fluid shifts and/or blood loss
**Use Black or Blue Ball Point Pen**

**All Entries Must Be Dated and Signed**

**ORDERS**

**DATE & TIME**

**GOAL:** Perioperative beta blockade

**TARGET:** Floor/ICU: HR greater than 50 and less than 70
OR: HR less than 70 bpm

**NOTE:** Hold beta blocker at any time if HR less than 50 bpm or SBP less than 90 mmHg
ECG monitoring required for giving IV beta-blocker

**ALLERGIES:**
- NKDA
- Yes, List:

**VITAL SIGNS:**
- HR and BP 1 hour after every oral dose of b-blocker
- HR and BP 10 min after every IV dose of b-blocker

**DOSSING PO:**
- If NPO, patient may still take beta blocker PO with sip of H2O
- Atenolol __mg PO q day Max dose 200 mg/day
- Metoprolol __mg PO q 12 hours Max dose 400 mg/day

**DOSSING IV:** Drug to be administered by slow IV push
- Metoprolol __mg IV q 6 h (Usual Dose- 5-15mg)

**DISCHARGE PLANNING:**
- Continue beta blocker PO for 7 days following surgery
- Continue beta blocker until seen by primary care physician

**DOSSING PARAMETERS:**

<table>
<thead>
<tr>
<th>HR</th>
<th>IV</th>
<th>PO</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 50</td>
<td>Hold all doses and notify MD</td>
<td>Hold all doses and notify MD</td>
</tr>
<tr>
<td>50-70</td>
<td>Decrease next dose by 50%</td>
<td>Decrease next dose by 50%</td>
</tr>
<tr>
<td>70-100</td>
<td>Increase next dose by 50%</td>
<td>Increase next dose by 50%</td>
</tr>
<tr>
<td>greater than 100</td>
<td>Double next dose</td>
<td>Double next dose</td>
</tr>
</tbody>
</table>

**Physician Signature:** ____________  **Carecast #:** ____________

---

**PERIOPERATIVE PROPHYLACTIC BETA BLOCKER PROTOCOL**

White Copy - Medical Record  Yellow Copy - Pharmacy  Pink Copy - Patient
Please complete after each surgical procedure and return, along with the usual self-assessment quality assurance sheet, to Anesthesia Administration.

**Question 1** – Does the patient meet the criteria for perioperative beta blocker use?
- Yes
- No - Stop data collection

**Question 2** – If yes, did the patient receive oral beta blockers pre-operatively?
- Yes – Go to Q4
- No – Go to Q3

**Question 3** – If not, did the patient receive intravenous beta blockers in the immediate perioperative period and intraoperatively?
- Yes – Go to Q4
- No – Go to Q4

**Question 4** – Were there any adverse events specifically related to the use of beta blockers?
- Yes
- No

***Anesthesia Administration:*** Please forward to Stephanie Gould at ZIP: 7465.
**DIFFICULT AIRWAY ALGORITHM**

1. Assess the likelihood and clinical impact of basic management problems:
   A. Difficult Intubation
   B. Difficult Ventilation
   C. Difficulty with Patient Cooperation or Consent

2. Consider the relative merits and feasibility of basic management choices:

   - **Non-surgical Technique for Initial Approach to Intubation** vs. **Surgical Technique for Initial Approach to Intubation**
   - **Awake Intubation** vs. **Intubation Attempts After Induction of General Anesthesia**
   - **Preservation of Spontaneous Ventilation** vs. **Ablation of Spontaneous Ventilation**

3. Develop primary and alternative strategies:

   - **A. AWAKE INTUBATION**
     - Airway Approached by Non-Surgical Intubation
     - Airway Secured by Surgical Access*
     - Succeed* vs. FAIL
     - Cancel Case vs. Consider Feasibility of Other Options (c)
     - Surgical Airway*

   - **B. INTUBATION ATTEMPTS AFTER INDUCTION OF GENERAL ANESTHESIA**
     - Initial Intubation Attempts Successful*
     - Initial Intubation Attempts UNSUCCESSFUL
     - FROM THIS POINT ONWARDS REPEATEDLY CONSIDER THE ADVISABILITY OF:
       1. Returning to spontaneous ventilation.
       2. Awakening the patient.
       3. Calling for help.

   - **NON-EMERGENCY PATHWAY**
     - Patient Anesthetized, Intubation Unsuccessful.
     - MASK VENTILATION ADEQUATE
     - Alternative Approaches to Intubation
     - Succeed* vs. FAIL After Multiple Attempts
     - Surgical Airway* vs. Surgery Under Mask Anesthesia vs. Awaken Patient (c)

   - **EMERGENCY PATHWAY**
     - Patient Anesthetized, Intubation Unsuccessful.
     - MASK VENTILATION INADEQUATE
     - Call For Help
     - One More Intubation Attempt
     - Succeed* vs. FAIL
     - Emergency Non-Surgical Airway Ventilation (d)
     - Emergency Surgical Airway* vs. Definitive Airway (c)

   - **IF MASK VENTILATION BECOMES INADEQUATE**
     - Succeed* vs. FAIL

---

* CONFIRM INTUBATION WITH EXHALED CO₂

(a) Other options include (but are not limited to): surgery under mask anesthesia, surgery under local anesthesia infiltration or regional nerve blockade, or intubation attempts after induction of general anesthesia.

(b) Alternative approaches to difficult intubation include (but are not limited to): use of different laryngoscope blades, awake intubation, blind oral or nasal intubation, fiber-optic intubation, intubating stylet or tube changer, light wand, retrograde intubation, and surgical airway access.

(c) See awake intubation.

(d) Options for emergency nonsurgical airway ventilation include (but are not limited to): transtracheal jet ventilation, laryngeal mask ventilation, or esophageal-tracheal combitube ventilation.

(e) Options for establishing a definitive airway include (but are not limited to): returning to awake state with spontaneous ventilation, tracheostomy, or endotracheal intubation.
<table>
<thead>
<tr>
<th>Pathologic State</th>
<th>Difficulty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious epiglottis</td>
<td>Laryngoscopy may worsen obstruction.</td>
</tr>
<tr>
<td>Abscess (submandibular, retropharyngeal, Ludwig’s angina)</td>
<td>Distortion of airway renders mask ventilation or intubation extremely difficult.</td>
</tr>
<tr>
<td>Croup, bronchitis, pneumonia (current or recent)</td>
<td>Airway irritability with tendency for cough, laryngospasm, bronchospasm</td>
</tr>
<tr>
<td>Papillomatosis</td>
<td>Airway obstruction</td>
</tr>
<tr>
<td>Tetanus</td>
<td>Trismus renders oral intubation impossible.</td>
</tr>
<tr>
<td>Traumatic foreign body</td>
<td>Airway obstruction</td>
</tr>
<tr>
<td>Cervical spine injury</td>
<td>Neck manipulation may traumatize spinal cord.</td>
</tr>
<tr>
<td>Basilar skull fracture</td>
<td>Basal intubation attempts may result in intracranial tube placement.</td>
</tr>
<tr>
<td>Maxillary/mandibular injury</td>
<td>Airway obstruction, difficult mask ventilation, and intubation; cricothyroidotomy may be necessary with combined injuries.</td>
</tr>
<tr>
<td>Laryngeal fracture</td>
<td>Airway obstruction may worsen during instrumentation. Endotracheal tube may be misplaced outside larynx and may worsen the injury.</td>
</tr>
<tr>
<td>Laryngeal edema (postintubation)</td>
<td>Irritable airway, narrowed laryngeal inlet</td>
</tr>
<tr>
<td>Soft tissue, neck injury (edema, bleeding, emphysema)</td>
<td>Anatomic obstruction of airway</td>
</tr>
<tr>
<td>Neoplastic upper airway tumors (harynx, larynx)</td>
<td>Airway obstruction</td>
</tr>
<tr>
<td>Neoplastic upper airway tumors (harynx, larynx)</td>
<td>Inspiratory obstruction with spontaneous ventilation</td>
</tr>
<tr>
<td>Lower airway tumors (trachea, bronchi, mediastinum)</td>
<td>Airway obstruction may not be relieved by tracheal intubation. Lower airway distorted</td>
</tr>
<tr>
<td>Radiation therapy</td>
<td>Fibrosis may distort airway or make manipulations difficult.</td>
</tr>
<tr>
<td>Inflammatory rheumatoid arthritis</td>
<td>Mandibular hypoplasia, temporomandibular joint arthritis, immobile cervical spine, laryngeal rotation, cricoarytenoid arthritis all make intubation difficult and hazardous.</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>Fusion of cervical spine may render direct laryngoscopy impossible.</td>
</tr>
<tr>
<td>Temporomandibular joint syndrome</td>
<td>Severe impairment of mouth opening</td>
</tr>
<tr>
<td>True ankylosis</td>
<td></td>
</tr>
<tr>
<td>“False” ankylosis (burn, trauma, radiation, temporal craniotomy)</td>
<td></td>
</tr>
</tbody>
</table>
Scleroderma  
Tight skin and temporomandibular joint involvement make mouth opening difficult.

Sarcoidosis  
Airway obstruction (lymphoid tissue)

Angioedema  
Obstructive swelling renders ventilation and intubation difficult.

Endocrine/metabolic acromegaly  
Large tongue, bony overgrowths

Diabetes mellitus  
May have reduced mobility of atlanto-occipital joint

Hypothyroidism  
Large tongue; abnormal soft tissue (myxedema) make ventilation and intubation difficult.

Thyromegaly  
Goiter may produce extrinsic airway compression or deviation.

Obesity  
Upper airway obstruction with loss of consciousness.  
Tissue mass makes successful mask ventilation unlikely.

Conditions Associated with Increased Risk of Aspiration

Full stomach (<8 hour fast), or vague history of intake

Gastrointestinal pathology (intestinal obstruction/inflammation; gastric paresis secondary to drugs, infection, uremia, diabetes mellitus)

Obesity

Pregnancy

Trauma

Esophageal disorders, for example, reflux, motility disorders


Protocol for Management of Surgical Patients

Preoperative Nothing by Mouth (NPO) Orders

1. Adults receiving general, regional, or monitored anesthesia care will be NPO after midnight preceding surgery.

2. Guidelines for NPO status in children:

<table>
<thead>
<tr>
<th>age</th>
<th>solids</th>
<th>clear liquids</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;6 mos.</td>
<td>4°</td>
<td>2°</td>
</tr>
<tr>
<td>6-36 mos.</td>
<td>6°</td>
<td>3°</td>
</tr>
<tr>
<td>3-6 yr.</td>
<td>8°</td>
<td>3°</td>
</tr>
</tbody>
</table>

6 years or older:
NPO after midnight or at least 8 hours prior to arrival time.

3. Patients receiving local anesthesia will follow any NPO instructions given by their surgeon. If no orders are given, the patient will be instructed to remain NPO after midnight.
PULMONARY FUNCTION TESTS

Physiological assessments

Physiological assessment tests are performed according to accepted protocols and the results are expressed as percents of established normals. Therapeutic bronchodilators should be withheld if possible before testing. Fig. 28-4 compares normal obstructive and restrictive ventilatory patterns. Table 28-1 summarizes pulmonary function testing abnormalities in common disorders.

1. The presence of obstructive disorders (e.g., bronchitis, asthma) is evidenced by reduced airflows:
   a. $\text{FEV}_1/\text{FVC}$: % predicted
       >80 normal
       65-79 mild obstructive disease
       50-64 moderate obstructive disease
       <50 severe obstructive disease
   b. $\text{FEF 25-75}$: indicates small airways
   c. Peak expiratory flow rate (PEFR): reflects mostly large airways
   d. $\text{FEF 50, 25}$: indicate small airways (flow-volume)
   e. Flow-volume tracing may also indicate extrathoracic obstruction, particularly in the inspiratory phase (Fig. 28-5 compares flow-volume curves in various disease states)
   f. Patients with COPD may have a mixture of reversible and irreversible airway obstruction
      (1) Improvement in $\text{FEV}_1 > 15\%$ after inhaled bronchodilator demonstrates reversibility
      (2) Negative response does not exclude reversibility, however, since patients can still have improvement in pulmonary function on long-term bronchodilator therapy

2. Increased residual volume (RV) on spirometry suggests hyperinflation (COPD, asthma); decreased RV occurs in restrictive disease (e.g., interstitial fibrosis) (Fig. 28-6 compares spirometric patterns in obstructive and restrictive disease)

3. Presence of restriction is manifested by a decrease in lung volumes, particularly VC and TLC; it occurs with neuromuscular, skeletal, pleural, and interstitial lung disorders

4. Diffusing capacity is reduced with interstitial disease, thickness of or loss of air exchange surface, and decreased ventilation or perfusion; useful as an early sign of emphysema or predictor of oxygen desaturation or poor exercise tolerance
Table 28-1  PFT abnormalities in common disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>FVC</th>
<th>FEV₁</th>
<th>FEV₁/FVC</th>
<th>RV</th>
<th>TLC</th>
<th>Diffusing Capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>N/↑</td>
<td>N</td>
</tr>
<tr>
<td>COPD</td>
<td>N/↓</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>N/↑</td>
<td>N/↓</td>
</tr>
<tr>
<td>Kyphoscoliosis</td>
<td>↓</td>
<td>↓</td>
<td>N/↑</td>
<td>N/↓</td>
<td>↓</td>
<td>N</td>
</tr>
<tr>
<td>Interstitial fibrosis</td>
<td>↓</td>
<td>↓</td>
<td>N/↑</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
</tbody>
</table>

KEY: ↓, Decreased; ↑, increased; N, normal; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 sec; RV, residual volume; TLC, total lung capacity

![Flow-volume curves](image)

**Figure 28-5**

Flow-volume curves of restrictive disease and various types of obstructive diseases compared with normal curves. FVC is functional vital capacity.

The Assessment of Dyspnea

Grade 0  No dyspnea while walking at a normal pace

Grade I  “I am able to walk as far as I like provided I take my time.”

Grade II Specific street block limitations – “I have to stop for a while after one or two blocks.”

Grade III Dyspnea on mild exertion – “I have to stop and rest while going from the kitchen to the bathroom.”

Grade IV Dyspnea at rest

Adapted from: Thomas M. Halaszynski, Richard Juda, David G. Silverman, “Optimizing postoperative outcomes with efficient preoperative assessment and management,” Critical Care Medicine, Volume 32, Number 4, (April 2004), S80


<table>
<thead>
<tr>
<th>TEST</th>
<th>SURGICAL PROCEDURES</th>
<th>CLINICAL DISORDERS</th>
<th>CONDITIONS/DRUGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>EKG</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>OCR &amp; PLT</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>CULTURE</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>CAIR</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>HORMONES LEVEL</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>BLOOD TIME</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>PREGNANCY</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>CARDIO/SEVERE PULMONARY DRUG LEVELS</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>CLDT</td>
<td>Depends on surgery/amount of blood loss anticipated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFT</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
<tr>
<td>SLEEP STUDY</td>
<td>+ + + + + + + + + +</td>
<td>+ + + + + + + + +</td>
<td>+ + + + + + + + +</td>
</tr>
</tbody>
</table>

* + needs - does not need
ASA 3-4 = workup within 72 hours
pregnancy screen
within 24 hours

COMPLETE C.S.P.N.: RHEUMATOID ARTHRITIS; DOWN'S SYNDROME; RECENT NECK INJURY

65
<table>
<thead>
<tr>
<th>Diagnostic</th>
<th>Hospital charge to patient</th>
<th>Pro-fee charge to patient</th>
<th>Total charge to patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>EKG</td>
<td>$247.60</td>
<td>$25.00</td>
<td>$272.60</td>
</tr>
<tr>
<td>Adult echocardiogram dop, color 2D</td>
<td>1,325.87</td>
<td>373.00</td>
<td>1,698.87</td>
</tr>
<tr>
<td>Adult transesophageal echocardiogram</td>
<td>1,509.73</td>
<td>521.00</td>
<td>2,030.73</td>
</tr>
<tr>
<td>Treadmill</td>
<td>827.33</td>
<td>152.00</td>
<td>979.33</td>
</tr>
<tr>
<td>Stress echo</td>
<td>1,762.18</td>
<td>429.00</td>
<td>2,191.18</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lab Test</th>
<th>Inpatient ($)</th>
<th>Outpatient ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC w/auto diff.</td>
<td>104.29</td>
<td>48.31</td>
</tr>
<tr>
<td>w/manual diff.</td>
<td>69.99</td>
<td>47.46</td>
</tr>
<tr>
<td>CBC, PLT</td>
<td>93.84</td>
<td>30.43</td>
</tr>
<tr>
<td>Hemoglobin &amp; Hematocrit ea</td>
<td>37.40 ea</td>
<td>14.77 ea</td>
</tr>
<tr>
<td>Plt. Count automated</td>
<td>37.40</td>
<td>37.40</td>
</tr>
<tr>
<td>Basic Metabolic Panel</td>
<td>230.89</td>
<td>46.09</td>
</tr>
<tr>
<td>Lytes</td>
<td>167.17</td>
<td>31.87</td>
</tr>
<tr>
<td>BUN/Creat.</td>
<td>BUN: 57.13/C: 81.89</td>
<td>BUN: 22.37/C: 22.37</td>
</tr>
<tr>
<td>K+</td>
<td>57.13</td>
<td>22.37</td>
</tr>
<tr>
<td>Complete Metabolic</td>
<td>352.91</td>
<td>73.16</td>
</tr>
<tr>
<td>Hepatic Function Panel</td>
<td>194.72</td>
<td>51.27</td>
</tr>
<tr>
<td>Mg+</td>
<td>93.62</td>
<td>37.45</td>
</tr>
<tr>
<td>Ca++</td>
<td>68.56</td>
<td>22.37</td>
</tr>
<tr>
<td>Calcium Ionized</td>
<td>121.81</td>
<td>43.91</td>
</tr>
<tr>
<td>Glucose (Quant.)</td>
<td>57.13</td>
<td>22.37</td>
</tr>
<tr>
<td>PT</td>
<td>76.11</td>
<td>22.43</td>
</tr>
<tr>
<td>PTT</td>
<td>76.33</td>
<td>22.43</td>
</tr>
<tr>
<td>TSH</td>
<td>132.74</td>
<td>69.85</td>
</tr>
<tr>
<td>T4, Free</td>
<td>132.74</td>
<td>69.85</td>
</tr>
<tr>
<td>UA (without micro)</td>
<td>35.84</td>
<td>12.20</td>
</tr>
<tr>
<td>UA with Microscopic</td>
<td>70.08</td>
<td>28.76</td>
</tr>
<tr>
<td>hCG serum</td>
<td>164.38</td>
<td>43.91</td>
</tr>
<tr>
<td>hCG urine or serum (qual.)</td>
<td>69.24</td>
<td>40.94</td>
</tr>
<tr>
<td>ABO</td>
<td>45.71</td>
<td>27.26</td>
</tr>
<tr>
<td>RH</td>
<td>49.23</td>
<td>27.76</td>
</tr>
<tr>
<td>AB (only)</td>
<td>87.93</td>
<td>62.93</td>
</tr>
<tr>
<td>Type &amp; Cross per unit</td>
<td>101.55*</td>
<td>85.52*</td>
</tr>
<tr>
<td>Blood Gas w/O₂ Sat</td>
<td>177.31</td>
<td>164.69</td>
</tr>
<tr>
<td>Blood Gas, Arterial</td>
<td>135.77</td>
<td>135.77</td>
</tr>
<tr>
<td>CXR pa/lat</td>
<td>266.33</td>
<td>266.33</td>
</tr>
</tbody>
</table>

*for two units this would double. Also, if the AB is positive or the type and crossmatch were incompatable, there would be additional charges.
New HCFA Chemistry Panels Compared With Previously Offered Panels At Clarkson and University Hospitals

**Electrolytes**
Phamis: LYTE1
- Sodium
- Potassium
- Chloride
- Carbon Dioxide
- Anion Gap
Inpatient Cost: 167.17  Outpatient Cost: 31.87

**Basic Metabolic Panel**
Phamis: BMET
- Glucose
- BUN
- Calcium
- Creatinine
- Sodium
- Postassium
- Chloride
- Carbon Dioxide
- BUN/CR
- Anion Gap
- Calc. Osmolality
Inpatient Cost: 230.89  Outpatient Cost: 46.09

**Comprehensive Metabolic Panel**
Phamis: CMET
- Glucose
- BUN
- Creatinine
- BUN/CR
- Sodium
- Potassium
- CO₂ and ALT
- Chloride
- Calc. Osmolality
- Calcium
- Total Protein
- Albumin
- AST
- ALK Phos.
- Total Billirubin
Inpatient Cost: 352.97  Outpatient Cost: 73.16
New HCFA Chemistry Panels Compared With Previously Offered Panels At Clarkson and University Hospitals

**Hepatic Function Panel**
Meditech: HEPFUNC  Phamis: HFP
  - Albumin
  - AST
  - ALT
  - ALK Phos.
  - Total Bilirubin
  - Direct Bilirubin
Inpatient Cost: 194.72  Outpatient Cost: 51.27

**Lipid Panel**
Meditech: LIPTID1  Phamis: LIPID
  - Cholesterol
  - Triglyceride
  - HDL
  - CHOL/HDL
  - LDL (calculated)
  - VLDL (calculated)
Inpatient Cost: 125.17  Outpatient Cost: 73.03

Please note: The Comprehensive Metabolic Panel and the Hepatic Function Panel may not be ordered simultaneously on a patient due to the duplication of panel components.
1. **Type & Screen:** unarmbanded specimen type: ABO/Rh, antibody screen

2. **Type & Possible:** armbanded specimen. Type: ABO/Rh, antibody screen. If screen is (+), then the antibody is identified and 2 Ag–units are crossmatched.

3. **Clot to Hold:** armbanded specimens. Specimen is processed and placed in storage in case of need for products.

4. **Type & Cross:** armbanded specimen. Type: ABO/Rh, antibody screen. If screen is (–), the # of units needed is crossmatched. If screen is (+), antibody identification & units “Ag–” are crossmatched.

**FOR #s 1–4...72 HOURS.**

5. **Extended Crossmatch.** This is valid if the patient has not been transfused with any blood products for 120 days or pregnant within 120 days. An armbanded specimen that is valid for 10 days from the date of draw. ABO/Rh, antibody screen & antibody identification if necessary, the day before surgery the units are crossmatched.
### Normal Ranges for Lab

**PT Prothrombin Time**  
11–13.8 seconds

**PTT Partial Thromboplastin Time**  
22–37 seconds

#### CBC

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC $\times 10^3$/MM$^3$</td>
<td>4–11</td>
<td>4–11</td>
</tr>
<tr>
<td>RBC</td>
<td>4.40–5.80</td>
<td>3.80–5.20</td>
</tr>
<tr>
<td>HGB</td>
<td>13–17</td>
<td>11.5–15.5</td>
</tr>
<tr>
<td>HCT%</td>
<td>37–51</td>
<td>35–46</td>
</tr>
<tr>
<td>MCV</td>
<td>82–98</td>
<td>89–92</td>
</tr>
<tr>
<td>MCH</td>
<td>27–33</td>
<td>27–33</td>
</tr>
<tr>
<td>MCHC%</td>
<td>32–36</td>
<td>32–36</td>
</tr>
<tr>
<td>RDW%</td>
<td>10.5–14.5</td>
<td>10.5–14.5</td>
</tr>
</tbody>
</table>

#### Differential Count (adults)

<table>
<thead>
<tr>
<th></th>
<th>%</th>
<th>Absolute # $\times 10^3$/MM$^3$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Segs</td>
<td>43–74</td>
<td></td>
</tr>
<tr>
<td>Bands</td>
<td>0–10</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>45–75</td>
<td>1.8–7.5</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>15–45</td>
<td>1.0–3.4</td>
</tr>
<tr>
<td>Monocytes</td>
<td>1–2</td>
<td>0.1–0.8</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0–6</td>
<td>$\leq$0.4</td>
</tr>
<tr>
<td>Basophils</td>
<td>0–2</td>
<td>$\leq$0.2</td>
</tr>
</tbody>
</table>
### Renal Panel

<table>
<thead>
<tr>
<th></th>
<th>Reference Range</th>
<th>Critical Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloride</td>
<td>95–110 mEq/L</td>
<td>&lt;70, &gt;120 mEq/L</td>
</tr>
<tr>
<td>CO2</td>
<td>22–30 mEq/l</td>
<td>&lt;10, &gt;40 mEq/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.9–1.3 mg/dl (adult male)</td>
<td>&gt;10 mg/dl</td>
</tr>
<tr>
<td></td>
<td>0.6–1.1 mg/dl (adult female)</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>3.5–4.7 mEq/L</td>
<td>&lt;2.5, &gt;6.5 mEq/L</td>
</tr>
<tr>
<td>Sodium</td>
<td>134–145 mEq/L</td>
<td>&lt;115, &gt;160 mEq/L</td>
</tr>
<tr>
<td>Urea nitrogen</td>
<td>5–22 mg/dl</td>
<td>&gt;100 mg/dl</td>
</tr>
<tr>
<td>Anion gap</td>
<td>4–15</td>
<td></td>
</tr>
</tbody>
</table>

**T4, Thyroxine, Total (adult) 4.5–11.5 ug/dl**

**TSH (Thyroid Stimulating Hormone) 0.4–5.0 uIU/ml**

Critical >100 uIU/ml

### Chemistry Profile

<table>
<thead>
<tr>
<th></th>
<th>Critical Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>3.6–5.0 g/dl</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>40–143 IU/L (adults ≥20 years)</td>
</tr>
<tr>
<td>AST (SGOT)</td>
<td>0–46 IU/L</td>
</tr>
<tr>
<td>Bilirubin (total)</td>
<td>0–1.2 mg/dl</td>
</tr>
<tr>
<td>Calcium</td>
<td>8.4–10.4 mg/dl</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>&lt;200 mg/dl</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.9–1.3 mg/dl (adult male)</td>
</tr>
<tr>
<td></td>
<td>0.6–1.1 mg/dl (adult female)</td>
</tr>
<tr>
<td>Glucose</td>
<td>60–110 mg/dl</td>
</tr>
<tr>
<td>LDH</td>
<td>100–250 IU/L</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>2.5–4.5 mg/dl</td>
</tr>
<tr>
<td>Protein, total</td>
<td>6.3–8.3 g/dl</td>
</tr>
<tr>
<td>Urea, nitrogen</td>
<td>5–22 mg/dl</td>
</tr>
<tr>
<td>Uric Acid</td>
<td>3.3 mg/dl–8.6 mg/dl male</td>
</tr>
<tr>
<td></td>
<td>2.5–7.5 mg/dl</td>
</tr>
</tbody>
</table>
Certain medications need to be stopped prior to surgery. If you are taking any of the following medications, please notify your physician to see what alternative medication you may be able to take, or if it is safe to discontinue the medication. Some medications may not be stopped abruptly, but may need to be weaned - CHECK WITH YOUR PRIMARY CARE PHYSICIAN. DO NOT STOP OTHER PRESCRIBED MEDS, i.e. blood pressure medication, thyroid meds, etc.

**Aspirin or aspirin containing products (Stop 2 weeks prior to surgery)**

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alka Seltzer</td>
<td>Bufferin</td>
</tr>
<tr>
<td>Anacin</td>
<td>Ecotrin</td>
</tr>
<tr>
<td>Ascriptin</td>
<td>Easprin</td>
</tr>
<tr>
<td>Aspergum</td>
<td>Empirin</td>
</tr>
<tr>
<td>Bayer</td>
<td>Excedrin</td>
</tr>
<tr>
<td>Generic Aspirin</td>
<td>Measurin</td>
</tr>
<tr>
<td>Measurin</td>
<td>Midol</td>
</tr>
<tr>
<td>Midol</td>
<td>Synalgos</td>
</tr>
<tr>
<td>Zorprin</td>
<td></td>
</tr>
</tbody>
</table>

**IMPORTANT NOTE IN BOXED AREA FOR ALL PATIENTS ON BLOOD THINNERS**

If you have had an MI, stroke/TIA (ministroke), CAD, angioplasty with/without stent placement, By-pass surgery, Atrial fibrillation, carotid surgery, or blood clot (in the leg or lung) check with your primary care physician or cardiologist before stopping ASA or “blood thinners”.

**“Blood thinners” / Antiplatelet**

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coumadin / warfarin</td>
<td></td>
</tr>
<tr>
<td>Dipyridamole / persantine</td>
<td></td>
</tr>
<tr>
<td>Plavix / clopidorel</td>
<td></td>
</tr>
<tr>
<td>Pletal / cilostazol</td>
<td></td>
</tr>
<tr>
<td>Ticlid / ticlopidine</td>
<td></td>
</tr>
<tr>
<td>Danaparoid (Orgaran)</td>
<td></td>
</tr>
<tr>
<td>Lovenox / enoxaparin</td>
<td></td>
</tr>
<tr>
<td>Fragmin / dalteparin</td>
<td></td>
</tr>
<tr>
<td>Innohep - Tinzaparin</td>
<td></td>
</tr>
<tr>
<td>Orgaran / danaparoid</td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td></td>
</tr>
<tr>
<td>Enoxaparin (Lovenox)</td>
<td></td>
</tr>
<tr>
<td>Dalteparin (Fragmin)</td>
<td></td>
</tr>
<tr>
<td>Tinzaparin</td>
<td></td>
</tr>
</tbody>
</table>

**Anti-inflammatory/NSAIDs (Stop 2 weeks prior to surgery)**

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advil</td>
<td></td>
</tr>
<tr>
<td>Aleve (naproxen sodium)</td>
<td></td>
</tr>
<tr>
<td>Anaprox (naproxen, naprelan, synflex)</td>
<td></td>
</tr>
<tr>
<td>Ansaid (flurbiprofen)</td>
<td></td>
</tr>
<tr>
<td>Cataflam (dicolfenac, voltaren, arthrotec)</td>
<td></td>
</tr>
<tr>
<td>Clinoril (sulidac)</td>
<td></td>
</tr>
<tr>
<td>Daypro (oxaprozin)</td>
<td></td>
</tr>
<tr>
<td>Disalcid (salsalate, salgesic, salflex, monogesic)</td>
<td></td>
</tr>
<tr>
<td>Feldene (piroxicam)</td>
<td></td>
</tr>
<tr>
<td>Indocin (indomethacin, haltran)</td>
<td></td>
</tr>
<tr>
<td>Lodine (etodolac)</td>
<td></td>
</tr>
<tr>
<td>Meclomen</td>
<td></td>
</tr>
<tr>
<td>Mefenamic acid (Ponstel)</td>
<td></td>
</tr>
<tr>
<td>Motrin (ibuprofen, rufen, meipren midol naprin)</td>
<td></td>
</tr>
<tr>
<td>Nalfon (fenoprofen)</td>
<td></td>
</tr>
<tr>
<td>Orudis (oravail, ketoprofen)</td>
<td></td>
</tr>
<tr>
<td>Relafen (nabumetone)</td>
<td></td>
</tr>
<tr>
<td>Tolectin (choline Mg, trisalicylate)</td>
<td></td>
</tr>
<tr>
<td>Toradol (acular, ketorolac)</td>
<td></td>
</tr>
</tbody>
</table>
Arthritis Medications (Stop 2 weeks prior to surgery)
  Cama arthritis  B/C powder arthritis

Migraine/Headache Medications (Stop 2 weeks prior to surgery)
  Fiorinal  Triaprin

Pain Medication (Stop 2 weeks prior to surgery)
  Equagesic  Roxiprin
  Norgesic  Salsalate
  Percodan  Trisalate (choline Magnesium trisalicylate)
  Robaxisal

Selective COX-2 inhibitors (Check with surgeon about stopping)
  Celecoxib (Celebrex)
  Rofecoxib (Vioxx) - If you were told to stop your aspirin or blood thinners you should stop your Vioxx as well.

All Diet Medications: Prescribed, Over-the-counter, Herbal
(Stop 2 weeks prior to surgery)
  Meridia
  Phentermine (ionamin, adipex)
  Metabolife
  Tenuate

All Herbal Medications / teas / supplements (Stop 2 weeks prior to surgery)
  i.e. Echinacea, Ephedra, Ginseng, Gingko, Goldenseal, Kava Kava, St. John’s Wort

Diet Supplements (Check with Primary Care physician about stopping)
  i.e., Protein Drinks
  Diet Drinks (SlimFast, etc.)
(This does not mean TPN, Tube Feeding, Ensure, etc. - Do as directed by surgery or anesthesia team)

Vitamins (Stop 10 days to 2 weeks prior to surgery, unless otherwise directed by surgeon)
  All mega dose vitamins, Vitamin E, anti-oxidants, fish oils

Medications for Ulcerative Colitis (check with primary care physician to see if you can stop meds)
  Rowasa / Pentasa / Asacol
  Sulfasalazine / azulfidine

Psychiatric Medications / Anxiety / Sleep Medication
(Do not stop abruptly, check with Primary Care physician about stopping meds, medication may need to be weaned or substituted)
  MAO inhibitors  Serzone  Trazadone (Desyrel)

***** STOP Alcohol products 48 hours prior to surgery. *****
***** STOP Tobacco products 24 hours prior to surgery. *****
***** STOP “street” / illicit drugs should be stopped 72 hours before surgery. *****
******** You MAY take Tylenol / Acetaminophen products for pain ********
Recognizing the Difference Between Drug Allergy and Drug Intolerance
(Adverse Drug Reactions)

Drug allergies are a special type of adverse drug reaction (ADR). The Textbook of Adverse Drug Reactions\(^1\) defines “drug allergy” as mediated by immunological mechanisms. Allergic drug reactions are categorized as a type B (bizarre) adverse drug reaction. These reactions are totally aberrant effects that are not to be expected from the known pharmacological actions of a drug when given in the usual therapeutic doses. They are usually unpredictable and are not observed during conventional pharmacological and toxicological screening programs. Although their incidence and morbidity are usually low, their mortality may be high.

In contrast, an intolerance to a drug is categorized as a type A (augmented) adverse drug reaction. These reactions are the result of an exaggerated, but otherwise normal, pharmacological action of a drug given in the usual therapeutic doses. Examples include bradycardia with beta-blockers, hemorrhage with anticoagulants, or drowsiness with benzodiazepines. Type A reactions are largely predictable on the basis of a drug’s known pharmacology. Drug therapy can often be continued with an alteration in dose or other intervention. They are usually dose-dependent and although their incidence and morbidity are often high, their mortality is generally low.

Why should we be concerned about the difference? Obviously, if a patient has a true allergy to a drug or class of drugs, we want to be aware not to expose the patient to a potentially dangerous or life-threatening situation. However, if a drug is listed as an allergy, but in actuality the patient has not demonstrated allergic symptoms but has experienced an intolerance such as nausea or gastrointestinal distress, the patient should not be precluded from future treatment with the drug as warranted.

Example: A patient comes to the emergency room with sustained chest pain and history of angina, hypertension, and coronary artery disease. The diagnosis of acute myocardial infarction is made following EKG and laboratory analysis. The treatment prescribed includes morphine. Morphine (and other narcotic analgesics to a lesser degree) is desirable for pain associated with ischemia because of its cardiovascular effects of venous pooling in the extremities causing decreased peripheral resistance. This effect results in decreases in venous return, cardiac work, and pulmonary venous pressure, thus decreasing oxygen demand by the heart.

When the patient’s old chart arrives, the allergy list includes morphine. When the family is interviewed, they describe the patient’s “allergy” as vomiting in response to morphine following a previous hospitalization. Morphine causes a central nervous system effect on the vomiting center to cause nausea and vomiting by depressing the vomiting center. An increase in vestibular sensitivity may also contribute to the high incidence of nausea and vomiting in ambulatory patients. By questioning the patient’s family, the emergency room staff was able to conclude that the patient was not truly allergic to morphine.

If allergies are not correctly identified in PHAMIS, people won’t know when to trust the information. Accurately describing an allergy vs. an intolerance will make sure patients are able to receive needed treatment when necessary and alert the health care team to actual allergic conditions which may preclude treatment with the offending drug.


Prepared by
Mary Windle, Pharm.D.
Drug Information Services
### Medication Allergies or Serious Adverse Drug Reactions

**Drug Name:** *(should this be from a list in order to allow PHAMIS to search for cross sensitivity)*

**Description of reaction** (check all that apply):

**Onset**
- [ ] immediate (within an hour following administration)
- [ ] delayed

**Severity**
- [ ] life-threatening
- [ ] resulted in hospitalization
- [ ] resulted in permanent disability
- [ ] required antidote or treatment to prevent impairment

**Respiratory Symptoms**
- [ ] shortness of breath
- [ ] respiratory distress
- [ ] wheezing/bronchospasm
- [ ] other (describe)

**Cardiovascular Symptoms**
- [ ] shock *(severe, abrupt hypotension)*
- [ ] hypertension
- [ ] cardiovascular arrest
- [ ] increased heart rate/palpitations

**Dermatologic**
- [ ] urticaria/hives
- [ ] itching, pruritus
- [ ] contact dermatitis
- [ ] other (describe)

**Additional Symptoms**
- [ ] fever
- [ ] diaphoresis
- [ ] generalized edema
- [ ] laryngeal or facial edema *(angioedema)*
- [ ] other (describe)
## Drug Toxicity Summary of the Toxic Reactions Reported to Commonly Used Chemotherapeutic Agents

<table>
<thead>
<tr>
<th>Reaction</th>
<th>HN</th>
<th>CTX</th>
<th>IFX</th>
<th>CLB</th>
<th>BUS</th>
<th>L-PAM</th>
<th>TT</th>
<th>NTU</th>
<th>MTX</th>
<th>5-FU</th>
<th>6-MP</th>
<th>ara-C</th>
<th>ACT D</th>
<th>ADR</th>
<th>DNR</th>
<th>MX</th>
<th>VCR</th>
<th>VLB</th>
<th>BLEO</th>
<th>MITO</th>
<th>DTC</th>
<th>PCZ</th>
<th>DDP</th>
<th>CP</th>
<th>L-ASP</th>
<th>VP-16</th>
<th>HU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>++</td>
<td>p</td>
<td>++</td>
<td>p</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever, chills</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>++</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatologic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>+</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local necrosis</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperpigmentation</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>+</td>
<td>+</td>
<td>p</td>
<td>+</td>
<td>+</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nail changes</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucositis</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>p</td>
<td>+</td>
<td>+</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lacrimal duct fibrosis</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diplopia</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrolbulbar neuritis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Necrosis</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other cardiac</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute infiltrate</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic fibrosis</td>
<td>p</td>
<td>+</td>
<td>+</td>
<td>p</td>
<td>+</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>*</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation, ileus</td>
<td>*</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Function tests</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholestatic jaundice</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parenchymal necrosis</td>
<td>*</td>
<td>*</td>
<td>p</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrosis, cirrhosis</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reaction</td>
<td>HN2</td>
<td>CTX</td>
<td>IFX</td>
<td>CLB</td>
<td>BUS</td>
<td>L-PAM</td>
<td>TT</td>
<td>NTU</td>
<td>MTX</td>
<td>5-FU</td>
<td>6-MP</td>
<td>ara-C</td>
<td>ACT-D</td>
<td>ADR</td>
<td>DNR</td>
<td>MX</td>
<td>VCR</td>
<td>VLB</td>
<td>BLEO</td>
<td>MITO</td>
<td>DTIC</td>
<td>PZ</td>
<td>DDP</td>
<td>CP</td>
<td>L-ASP</td>
<td>VP-16</td>
<td>HU</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-------</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
<td>------</td>
<td>-----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>----</td>
<td>-----</td>
<td>----</td>
<td>-------</td>
<td>-------</td>
<td>----</td>
</tr>
<tr>
<td><strong>Renal/metabolic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxic nephropathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIADH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary retention</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hematologic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marrow</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Megaloblastosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemolytic anemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neurologic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebellar ataxia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ototoxicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Encephalopathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(Neurologic—continued)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Stroke-like</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(see text for intrathecal side effects)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raynaud’s syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiation recall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic cystitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pseudohypothyroidism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parotid pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Radiation:** Radiation therapy to the mediastinum may injure the pericardium and myocardium. (dose dependent 5% of patients with ≥ 4000 rads to more than 50% of their heart).... Acute pericarditis typically appears within a year of therapy and may result in tamponade. Chronic pericarditis usually causes an asymptomatic pericardial effusion presenting several years after therapy. Chronic pericarditis may resolve spontaneously or may progress to constrictive pericarditis...... Radiation injury to the myocardium can cause premature coronary artery disease. The overall incidence is low, but risk increases with higher doses, particularly with those delivered to an anterior field..... Patients with a history suggestive of myocardial ischemia who have received mediastinal irradiation should be carefully evaluated regardless of age. It may well be more than ten years before coronary artery disease appears. The electrocardiogram may be abnormal in many patients but may not predict coronary or pericardial disease. From *Perioperative Medicine 2nd ed.* Goldman, Brown. “Surgery in the Patient with Cancer” pg. 289

Abbreviations used for the drugs are as follows: nitrogen mustard, HN$_2$; cyclophosphamide, CTX; Ifosfamide, IFX; chlorambucil, CLB; busulfan, BUS; l-phenylalanine mustard, l-PAM; thiotope, TT; the nitrooureas, NTU; methotrexate, MTX; 5-fluorouracil, 5-FU; 6-mercaptopurine, 6-MP; cytosine arabinoside, ara-C; actinomycin D, ACT D; doxorubicin, ADR; daunorubicin, DNR; mitoxantrone, MX; vincristine, VCR; vinblastine, VLB; bleomycin, BLEO; mitomycin C, MITO; Dacarbazine® (Miles), DTIC; procarbazine, PCZ; cisplatin, DDP; carboplatin CP; l-asparaginase, l-ASP; etoposide, VP-16; and hydroxurea, HU.

The side effects to the nitrosoureas are quite similar and these agents have not been subcategorized. Several agents have been omitted: mithramycin, which causes hypocalcemia, liver toxicity, and facial flushing; and hormonal agents (androgens, estrogens, anitestrogens, progestagens, and adrenal corticosteroids), which cause uniform predictable side effects characteristic of each hormone. Experimental drugs and a few other little-used agents have been omitted.

**Key:**

- indicates a side effect has not been reported.
  p indicates a side effect is possibly associated or has been reported very rarely.
  + indicates a side effect has been observed and may, on occasion, present a clinical problem.
  ++ indicates a common and/or unusually severe side effect.
  DL indicates a dose-limiting side effect.

*Chemotherapy Source Book*

*Michael Perry, M.D., ACP, 1992*

*pg. 1141-1143*
Approximate Risk for Transmitting an Infectious Agent via Blood Products

Hepatitis B virus .................1 in 63,000

Hepatitis C virus ...................0.03%/unit transfused (1990. With improved testing in 1992, may now be lower.)

(90% post-transfusion hepatitis

HIV infection ..................*1:450,000–1:660,000 per transfused unit of blood

The period between viral infection and its detection by tests for the presence of antibodies is approximately 22 days.

* Higher rates may occur in areas with increased HIV prevalence.
* HIV-1 Ag. tests (donor screening) are expected to prevent 25% of window period cases (5–10 cases/year).

Other Infectious Diseases

Bacterial sepsis
Babesia
Malaria
Syphilis
All rare; no accurate data available.
Parasitic and bacterial—possibly 1:1,000,000
Chagas’ disease 1:42,000
FDA reported cases, 1976–1985=26 deaths due to bacterial contamination of blood components
RBC 1:500,000
PHS 1:10,000-20,000

Nonhemolytic transfusion reactions occur in approximately 1–5% of all transfusions.

The estimated risk of ABO-incompatible transfusion is 1:12,000 RBC transfusions.

The probability of a fatal hemolytic transfusion reaction is uncertain with estimates ranging from 1:500,000 to 1:800,000 (1976–1985=131 fatal ABO-incompatible transfusions reported to FDA.)

Approximately 12,000,000 units of RBCs are transfused each year in the U.S.
More than 7,000,000 units of platelets are transfused each year in the U.S.
Approximately 2,000,000 units of FFP are transfused each year in the U.S.
Almost 1,000,000 units of cryoprecipitate are transfused each year in the U.S.


<table>
<thead>
<tr>
<th>Department</th>
<th>Extension</th>
<th>Pager</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMITTING</td>
<td>9-4222</td>
<td>#0886</td>
</tr>
<tr>
<td>ANESTHESIA</td>
<td></td>
<td>#6006/#7777</td>
</tr>
<tr>
<td>CATH LAB</td>
<td>2-3391</td>
<td></td>
</tr>
<tr>
<td>CARDIOLOGY CLINIC</td>
<td>9-8888</td>
<td></td>
</tr>
<tr>
<td>Clinic FAX</td>
<td>559-3060</td>
<td></td>
</tr>
<tr>
<td>Cardiology FAX</td>
<td>559-3060</td>
<td></td>
</tr>
<tr>
<td>DIAGNOSTIC CENTER</td>
<td>9-8780</td>
<td></td>
</tr>
<tr>
<td>HEART STATION</td>
<td>9-4143</td>
<td></td>
</tr>
<tr>
<td>ECHO NURSE</td>
<td></td>
<td>#1829</td>
</tr>
<tr>
<td>EKG TECH</td>
<td></td>
<td>#1166</td>
</tr>
<tr>
<td>ER</td>
<td>9-4020</td>
<td></td>
</tr>
<tr>
<td>LAB</td>
<td>9-4255</td>
<td></td>
</tr>
<tr>
<td>Chemistry</td>
<td>9-4255</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>9-7640</td>
<td></td>
</tr>
<tr>
<td>Microbiology</td>
<td>9-7667</td>
<td></td>
</tr>
<tr>
<td>MED RECORDS</td>
<td>9-4024</td>
<td></td>
</tr>
<tr>
<td>PASTORAL CARE</td>
<td>9-4176</td>
<td></td>
</tr>
<tr>
<td>PHARMACY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inpatient</td>
<td>9-7235</td>
<td></td>
</tr>
<tr>
<td>Outpatient</td>
<td>9-5216</td>
<td></td>
</tr>
<tr>
<td>PRE-SURGICAL TESTING</td>
<td>9-9228</td>
<td></td>
</tr>
<tr>
<td>FAX</td>
<td>559-9226</td>
<td></td>
</tr>
<tr>
<td>PA Barb Sink</td>
<td></td>
<td>#2282</td>
</tr>
<tr>
<td>Anesthesiology</td>
<td></td>
<td>#0879</td>
</tr>
<tr>
<td>PA Christy Shearer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Hurlbert</td>
<td>9-4081</td>
<td></td>
</tr>
<tr>
<td>PULMONARY LAB</td>
<td>9-4430</td>
<td></td>
</tr>
<tr>
<td>RADIOLOGY</td>
<td>9-1000</td>
<td></td>
</tr>
<tr>
<td>SOCIAL SERVICE</td>
<td>9-4420</td>
<td></td>
</tr>
<tr>
<td>SURGERY SCHEDULE</td>
<td>9-9900</td>
<td></td>
</tr>
<tr>
<td>THORACIC</td>
<td>9-4424</td>
<td></td>
</tr>
<tr>
<td>TRANSCRIPTION</td>
<td>9-4151</td>
<td></td>
</tr>
<tr>
<td>UNIVERSITY HOUSE</td>
<td>9-5599</td>
<td></td>
</tr>
</tbody>
</table>

(7/1/03)
### TEMPERATURE CONVERSION CHART

<table>
<thead>
<tr>
<th>Degree $F^\circ$</th>
<th>Degree $C^\circ$</th>
<th>Degree $F^\circ$</th>
<th>Degree $C^\circ$</th>
</tr>
</thead>
<tbody>
<tr>
<td>96.8</td>
<td>36.0</td>
<td>100.6</td>
<td>38.1</td>
</tr>
<tr>
<td>97.0</td>
<td>36.1</td>
<td>100.8</td>
<td>38.2</td>
</tr>
<tr>
<td>97.2</td>
<td>36.2</td>
<td>100.9</td>
<td>38.3</td>
</tr>
<tr>
<td>97.3</td>
<td>36.3</td>
<td>101.1</td>
<td>38.4</td>
</tr>
<tr>
<td>97.5</td>
<td>36.4</td>
<td>101.3</td>
<td>38.5</td>
</tr>
<tr>
<td>97.7</td>
<td>36.5</td>
<td>101.5</td>
<td>38.6</td>
</tr>
<tr>
<td>97.9</td>
<td>36.6</td>
<td>101.7</td>
<td>38.7</td>
</tr>
<tr>
<td>98.1</td>
<td>36.7</td>
<td>101.8</td>
<td>38.8</td>
</tr>
<tr>
<td>98.2</td>
<td>36.8</td>
<td>102.0</td>
<td>38.9</td>
</tr>
<tr>
<td>98.4</td>
<td>36.9</td>
<td>102.2</td>
<td>39.0</td>
</tr>
<tr>
<td>98.6</td>
<td>37.0</td>
<td>102.4</td>
<td>39.1</td>
</tr>
<tr>
<td>98.8</td>
<td>37.1</td>
<td>102.6</td>
<td>39.2</td>
</tr>
<tr>
<td>98.9</td>
<td>37.2</td>
<td>102.7</td>
<td>39.3</td>
</tr>
<tr>
<td>99.1</td>
<td>37.3</td>
<td>102.9</td>
<td>39.4</td>
</tr>
<tr>
<td>99.3</td>
<td>37.4</td>
<td>103.1</td>
<td>39.5</td>
</tr>
<tr>
<td>99.5</td>
<td>37.5</td>
<td>103.3</td>
<td>39.6</td>
</tr>
<tr>
<td>99.7</td>
<td>37.6</td>
<td>103.5</td>
<td>39.7</td>
</tr>
<tr>
<td>99.9</td>
<td>37.7</td>
<td>103.6</td>
<td>39.8</td>
</tr>
<tr>
<td>100.0</td>
<td>37.8</td>
<td>103.8</td>
<td>39.9</td>
</tr>
<tr>
<td>100.2</td>
<td>37.9</td>
<td>104.0</td>
<td>40.0</td>
</tr>
<tr>
<td>100.4</td>
<td>38.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
• Calculation of creatinine clearance (CCr)

\[
CCr \ (male) = \frac{(140 - \text{age}) \times \text{wt} \ (\text{in kg})}{\text{Serum creatinine} \times 72}
\]

\[
CCR \ (female) = 0.85 \times CCr \ (male)
\]

• Alveolar-arterial oxygen gradient (Aa gradient)

\[
\text{Aa Gradient} = \left(713 \times \left(\text{Flo}_2 - \frac{\text{Paco}_2}{0.8}\right)\right) - \text{Pao}_2
\]

Normal Aa gradient = 5-15 mm
\[
\text{Flo}_2 = \text{Fraction of inspired oxygen (normal = 0.21-1.0)}
\]
\[
\text{Paco}_2 = \text{Arterial carbon dioxide tension (normal = 35-45 mmHg)}
\]
\[
\text{Pao}_2 = \text{Arterial partial pressure oxygen (normal = 70-100 mmHg)}
\]

Differential diagnosis of Aa gradient:

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>15% O₂</th>
<th>100% O₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diffusion defect</td>
<td>Increased gradient</td>
<td>Correction of gradient</td>
</tr>
<tr>
<td>Ventilation/Perfusion mismatch</td>
<td>Increased gradient</td>
<td>Partial or complete correction of gradient</td>
</tr>
<tr>
<td>Right-to-left shunt (intracardiac or pulmonary)</td>
<td>Increased gradient</td>
<td>Increased gradient (no correction)</td>
</tr>
</tbody>
</table>

* Anion gap

\[
\text{AG} = \text{Na}^+ - (\text{Cl}^- + \text{HCO}_3^-)
\]

• Fractional excretion of sodium

\[
\text{FE}_{\text{Na}} = \frac{\text{U}_{\text{Na}}/\text{P}_{\text{Na}}}{\text{U}_{\text{Cr}}/\text{P}_{\text{Cr}}} \times 100
\]

• Serum osmolality

\[
\text{Osm} = 2 \times (\text{Na}^+ + \text{K}^+) + \frac{\text{Glucose}}{18} + \frac{\text{BUN}}{2.8}
\]

Corrected sodium in hyperglycemic patients

\[
\text{Corrected Na}^+ = \text{Measured Na}^+ + 1.6 \times \frac{\text{Glucose} - 140}{100}
\]

Water deficit in hypernatremic patients

\[
\text{Water deficit (in liters)} = 0.6 \times \text{body weight (kg)} \times \frac{\text{Measured serum sodium}}{\text{Normal serum sodium}}
\]
1. Temperature
   a. $^{\circ}C = (^{\circ}F - 32) \times \frac{5}{9}$
   b. $^{\circ}F = (^{\circ}C \times \frac{9}{5}) + 32$

2. Weight
   a. 1 lb = 0.454 kg
   b. 1 kg = 2.204 lb
   c. 10 grains = 650 mg
   d. 400 micrograms = 1/150 grain

3. Length
   a. 1 inch = 2.54 cm
   b. 1 cm = 0.3937 inch

### Nomogram

<table>
<thead>
<tr>
<th>Height cm</th>
<th>For children of normal height for weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>240</td>
<td>90</td>
</tr>
<tr>
<td>220</td>
<td>70</td>
</tr>
<tr>
<td>200</td>
<td>50</td>
</tr>
<tr>
<td>180</td>
<td>30</td>
</tr>
<tr>
<td>160</td>
<td>10</td>
</tr>
<tr>
<td>140</td>
<td>5</td>
</tr>
<tr>
<td>120</td>
<td>2</td>
</tr>
<tr>
<td>100</td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
</tr>
</tbody>
</table>

### BMI Metric Formula

BMI = Weight [in kilos] divided by (Height [in meters] X Height [in meters]) or:

### BMI Pounds/Inches Formula

BMI = Weight [in pounds] X 704.5 divided by (Height [in inches] X Height [in inches])